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ABSTRACT OF FINDINGS
Background: Ductal carcinoma in situ (DCIS) of the breast is being diagnosed 
with increasing frequency, partly due to the increased use of mammography in 
mass screening programs. The precise natural history of DCIS is not clear but is 
thought to represent a stage in the progression to frank malignancy. This group 
has previously described a radioimmunohistochemical technique which allows 
quantitation of the EGFR and HER2 in all cases of tumour examined (1;2). 
Application of this quantitative radioimmunohistochemistry to pure DCIS, DCIS 
in association with invasive disease and primary invasive breast cancers may 
clarify the role, if any, of EGFR and HER2 in the pathogenesis of invasive breast 
cancer. If EGFR downregulation or HER2 overexpression are required for 
progression to invasion we might expect to see more lesions with normal levels of 
expression in pure DCIS, and an invasive or intermediate pattern in DCIS 
adjacent to invasive areas. In this way, the quantitative information available from 
radio-immunohistochemistry may allow us to predict the biological role of EGFR 
and HER2 in breast carcinogenesis and progression.
HER2 gene amplification or protein overexpression identifies 20-30% of breast 
cancer patients with a poor outlook. Current methods of HER2 analysis reveal 
nothing about the remaining 70 to 80% of patients. This may compromise the 
prognostic or predictive value of HER2.
Methods: In frozen sections of pure DCIS tumours (n=37 for EGFR, n=36 for 
HER2) and in DCIS lesions in association with invasive cancers, (n=50 for EGFR, 
n=47 for HER2) receptor levels were assayed quantitatively using a radiolabelled 
antibody method. EGFR was quantified in 193 and HER2 in 177 frozen primary
breast tumours using radioimmunohistochemistry. The results of HER2 
expression were related to patient survival and major pathological variables. 
Results: EGFR and HER2 expression each varied by a factor of several thousand. 
Levels of EGFR and HER2 expression in pure DCIS, in DCIS associated with 
invasion and in a larger group of invasive tumours (n=T93 for EGFR, n=177 for 
HER2) were compared. The frequency distributions for expression of both factors 
were comparable in pure DCIS and in DCIS associated with invasive tumours 
(Mann-Whitney U test, EGFR p=0.17, HER2 p=0.16). Similarly, frequency 
distributions for expression of both factors were comparable in DCIS associated 
with invasive tumours and in purely invasive tumours (Mann-Whitney U test, 
EGFR p=0.16, HER2 p=0.91). Comparing pure DCIS with invasive tumours , 
there was a trend to significance difference in the frequency distributions of these 
2 growth factor receptors. Within each tumour that had both DCIS and invasion, 
there was no significant difference in expression of EGFR or HER2 in the DCIS 
and invasive components (Wilcoxon Signed Rank Test, EGFR p=0.39, HER2 
p=0.087). However, on reviewing individual cases, those tumours that exhibit the 
largest change in expression of growth factor receptor between the DCIS and 
invasive components appeared to have very aggressive invasive tumours.
Fifteen percent of primary invasive cancers expressed less HER2 than normal 
breast parenchyma, 62% had between 1 and 15 times normal and 23% between 15 
and 400 fold overexpression. We have shown previously that this last group 
corresponds to those with HER2 gene amplification. Survival analysis indicated 
that prognosis was best for tumours with intermediate levels of HER2, becoming 
worse for both lower and higher expressing cases. The best outcome was
associated with a 5.7 times the normal HER2 level. The relative hazard was 3.5 
times higher for tumours with O.lx normal expression, and 4 times higher for 
tumours with lOOx normal expression. HER2 remained a significant predictor of 
survival when the pathological variables were introduced into the analysis. 
Conclusions: These data suggest that alterations in type I growth factor receptors 
occur before progression of in-situ disease to invasive cancer. High levels of 
HER2 overexpression in both in-situ and invasive areas suggest that the HER2 
product is a potential therapeutic target for the treatment of breast cancer at an 
early stage. In addition, these results indicate that the role of HER2 in breast 
cancer is complex, as tumours with down regulation as well as those with gene 
amplification exhibit more aggressive behaviour. These findings are of clinical 
importance given the developing role of HER2 as a prognostic and predictive 
factor, and as a target for therapy.
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SECTION 1 INTRODUCTION
1.1 OVERVIEW
Ductal carcinoma in situ (DCIS) of the breast is being diagnosed with increasing 
frequency, partly due to the increased use of mammography in mass screening 
programs. The precise natural history of DCIS is not clear but is thought to 
represent a stage in the progression to frank malignancy.
EGFR and HER2 have been extensively studied in breast cancer. This group has 
previously described a radioimmunohistochemical technique which allows 
quantitation of the EGFR and HER2 in all cases (1 ;2).
This work has applied this method to DCIS lesions and to primary invasive breast 
cancers in two ways:
1. application of quantitative radioimmunohistochemistry to pure DCIS, DCIS in 
association with invasive disease and primary invasive breast cancers to 
clarify the role, if any, of EGFR and HER2 in the pathogenesis of invasive 
breast cancer.
2. to expand the number of tumours examined in the previous studies from 118 
to 193 for EGFR and from 81 to 177 for HER2. In addition the long term 
follow up of patients for whom quantitative HER2 measurements were made 
is presented.
1
1.2 In situ carcinoma of the breast
During the past decade, as mammography has become more widely used and 
technically advanced, the prevalence of lesions that appear to be in the early 
stages of tumour development has been emphasized. In situ carcinoma of the 
breast is an example of such an early lesion. As in other parts of the body these in 
situ lesions show some of the cytological properties of infiltrative tumours, but 
have not yet begun to infiltrate themselves. The implication is that they might do 
so if left for long enough although the length of time is unknown. Intense research 
is now being directed at determining how far these lesions have evolved from 
normality in terms of time and biological events and whether any of these events 
are reversible. In situ carcinoma of the breast may then be a potential candidate 
for targetted anti-cancer therapy allowing early treatment before progression to 
frank invasion.
1.2.1 Types of in situ breast carcinoma
Carcinoma in situ was originally classified as ductal or lobular based on the 
resemblance of involved spaces to ducts and lobules. These descriptive terms are 
still in use although all carcinomas are now thought to arise from the terminal duct 
lobular unit and the terms no longer imply a site or cell type of origin (3).
The 2 types are:
• lobular carcinoma in situ (LCIS)
• ductal carcinoma in situ (DCIS)
2
1.3 Lobular carcinoma in situ (LCIS)
LCIS is much less common than ductal carcinoma in situ (DCIS) and is usually an 
incidental finding in breast tissue removed for other reasons. In contrast with 
DCIS, LCIS is often multifocal and bilateral in up to 30% of cases. The term 
lobular carcinoma in situ (LCIS) is misleading and is more appropriately termed 
"lobular neoplasia." Strictly speaking, it is not known to be a premalignant lesion, 
but rather a marker that identifies women at an increased risk for subsequent 
development of invasive breast cancer. This risk remains elevated even beyond 2 
decades, and most of the subsequent cancers are ductal in nature rather than 
lobular. In a large prospective series from the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) with 5-year follow-up of 182 women with LCIS 
managed with excisional biopsy alone, only 8 women developed ipsilateral breast 
cancer (4 of them invasive) (4). In addition, 3 developed contralateral breast 
tumors (2 of them invasive).
LCIS will not be considered further in this work as it forms no part of this study.
3
1.4 Ductal carcinoma in situ (DCIS)
DCIS is a proliferation of malignant epithelial cells within the ductolobular 
system of the breast that show no light microscopic evidence of invasion through 
the basement membrane into the surrounding stroma.
1.4.1 Incidence of DCIS
Until the late 1970’s, DCIS was an uncommon disease, representing only about 
1% of all newly diagnosed cases of breast cancer (5). Then, most patients 
presenting with DCIS had symptoms -  a palpable mass or discharge from the 
nipple. The incidence of DCIS has increased in recent years, partly because 
screening mammography is more refined and more widely used (6-9). During 
1997, more than 36 000 new cases of DCIS, representing 17% of all new breast 
cancers, were diagnosed in the United States (10). The rate of increase in 
incidence has been higher for DCIS than for any other type of breast cancer (11). 
The reported incidence in women 50 years of age or older increased 235% from 
1979 to 1986; in contrast, the incidence of invasive cancer increased 50% (12). 
Wider use and greater acceptance of screening policies as well as technological 
advances in mammographic techniques do not seem to fully explain the increasing 
incidence of DCIS. Data from the metropolitan Atlanta Surveillance, 
Epidemiology, and End Results (SEER) study (1979 to 1986) showed that 
asymptomatic tumors (those detected on screening mammography alone) 
accounted for only 25% to 40% of the increase in incidence (13). These reports 
suggest that increased detection accounts for some but not all of the increase in 
incidence. The National Cancer Institute SEER data for the entire United States 
confirmed this trend (14). Overall, the total number of cases of DCIS in 1992 was
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200% greater (23 368 cases) than expected for that year as calculated from the 
trends between 1973 and 1983. Apart from increased detection, it is at present 
unclear why the incidence of DCIS has increased so dramatically. With this vast 
increase in diagnosis, our understanding of DCIS as a single disease has 
evaporated. It is now well recognised as a heterogeneous group of lesions with a 
diverse malignant potential.
The exact incidence of DCIS in the general population is unknown. In an autopsy 
study of 519 women of various ethnic backgrounds, only one case (0.2%) of DCIS 
was found (15). In this study of 519 women, only 117 were older than 55 years of 
age. Alpers and Wellings (16) performed autopsies on 185 patients, of whom 9 
(4.9%; 11 breasts) had evidence of the tumor on subgross sampling (17). The 
findings of autopsy studies suggest that incidental DCIS of uncertain clinical 
relevance is not common. Variations in incidence seen in published autopsy 
studies is likely to reflect differences in sampling techniques and diagnostic 
criteria. Ductal carcinoma in situ of the male breast represents 3.5% to 7% of all 
cases of male breast cancer (18).
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1.4.2 Pathology of DCIS
DCIS is characterized by a proliferation of malignant looking epithelial cells 
within the mammary ductal-lobular system that show no light microscopic 
evidence of invasion into the surrounding stroma and therefore, an intact 
basement membrane.
Traditional methods of classifying DCIS were based on the architectural pattern of 
the lesion. The most common types are designated comedo, cribriform, 
micropapillary, papillary, clinging and solid. Examples of these are shown in 
Figures 1-4.  This method was initially recommended for use in the UK National 
Breast Screening Programme (19).
These initial methods paid little attention to cytologic features and proved 
unsatisfactory for a number of reasons:
• Larger lesions showed considerable variations in architectural pattern even 
within the same slide and occasionally within a single terminal ductal lobular 
unit.
• The criteria are subjective and ill defined, allowing for a high level of 
interobserver variation. In a study assessing the consistency of 
histopathological reporting in the UK National Breast Screening Programme 
there was very low agreement in classifying DCIS when doing so by 
predominant architecture alone (20).
These factors help explain the varying incidence of the different subtypes in 
reported series of DCIS (21) and the differences in the reported incidence of 
subsequent invasive carcinoma following the various subtypes of DCIS
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undergoing treatment with breast conservation therapy. As the incidence of DCIS 
increases it becomes more important that the biology of the disease is understood. 
Many pathologists believe it is useful to subdivide DCIS into two groups -  the 
comedo and the noncomedo type, although this is controversial.
This preference is based on the observation that comedo DCIS
• appears more malignant cytologically (22;23),
• is more often associated with microinvasion (24-26),
• more often exhibits biologic markers indicative of high-grade malignant 
lesions than do the other types,
• more frequently lacks oestrogen receptors (27),
• has a high proliferative rate (28),
• more frequently exhibits aneuploidy (29),
• more frequently overexpresses the HER2 oncogene (30-32),
• shows mutations of the p53 tumour suppressor gene with accumulation of its 
protein product (33;34),
• more frequently exhibits angiogenesis in the surrounding stroma (35),
• has been shown to have a higher risk of local recurrence (36).
The comedo necrosis type of DCIS is diagnosed when at least one duct in the 
breast is filled and expanded by large, markedly atypical cells and has abundant 
central luminal necrosis.
All other forms of DCIS are of the noncomedo necrosis type and include the 
cribriform, micropapillary, and solid types. Many examples of the noncomedo 
necrosis type consist of a combination of the various histologic patterns. Although
7
necrosis may be present, it is less prominent than in the comedo necrosis type and 
is not as prone to calcification.
Necrosis within 
duct. The 
surrounding cells 
show high grade 
nuclear atypia.
Figure 1. Comedo type DCIS. Medium power. Haematoxylin and eosin stain. Solid 
sheets o f malignant cells fill the dilated ducts. The centre o f the involved ducts 
undergoes necrosis and calcification.
Multiple sieve-like 
glandular spaces occur 
within a large duct 
(arrows).
Figure 2. Cribriform type DCIS. Low power. Haematoxylin and eosin stain. The 
growth pattern, called cribriform, has multiple round spaces within each duct. 
Some o f  these spaces may contain microcalcifications.
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The dilated ducts are 
lined by multiple 
finger-like projections 
(white arrows)
Figure 3. Micropapillary type DCIS. Medium power. Haematoxylin and eosin 
stain.
Solid filling o f the 
ducts by malignant 
cells without
necrosis.
Figure 4. Solid type DCIS. Medium power. Haematoxylin and eosin stain.
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In the 1980’s Lagios drew attention to the value of nuclear grade and necrosis as 
predictors of disease recurrence following wide excision of DCIS (37). This has 
subsequently been supported by several studies (38-40). Various classification 
systems have now been proposed, based on one or more of the following features: 
nuclear differentiation, the presence or absence of necrosis, growth patterns, 
tumour size and architectural differentiation. The optimal classification scheme 
for DCIS remains controversial.
Recently revised guidelines for pathology reporting in the UK NHS breast 
screening programme recommend a classification of DCIS based entirely on 
nuclear grading because all the major classifications reflect nuclear grade. DCIS is 
divided into high, intermediate and low grades. The defining nuclear features in 
this system were originally defined by a European group of pathologists (38). 
High grade DCIS is composed of cells with markedly pleomorphic nuclei, coarse 
clumped chromatin, prominent nucleoli and frequent mitoses. Intermediate grade 
lesions have pleomorphic cells, which do not show such variation in size as in the 
high grade group, chromatin is fine to coarse, nucleoli are present but not 
prominent and mitoses are occasionally present. In the low grade group, nuclei are 
monomorphic with fine chromatin, insignificant nucleoli and few mitoses.
At a recent consensus conference, it was suggested that, while categorizing DCIS 
according to nuclear grade, other features, in particular the presence or absence of 
necrosis and of cellular depolarisation and the architectural growth pattern, should 
also be recorded. In addition, margins, lesion size, microcalcification associated 
with DCIS, correlation of DCIS with specimen x-ray and mammographic
10
findings, and the presence of any microinvasion should all be documented in the 
pathology report (41).
The introduction of breast conservation therapy for invasive breast cancer in the 
early 1980’s led to pressure for the use of this form of therapy for carcinoma in 
situ. In the USA, between 1983 and 1992, there was a marked decline in the 
proportion of cases treated by mastectomy (from 71% to 43.8%) and an increase 
in those treated by lumpectomy (from 25.6% to 53.3%) (14). The need for 
assessment of the risk of both recurrence and, more importantly, subsequent 
development of invasive disease has, therefore, been emphasised. This has 
highlighted not only the importance of histology in the diagnosis of DCIS but also 
in the morphological classification of the lesion. The importance of nuclear grade 
in DCIS has been recognised and the presence or absence of necrosis has also 
been considered of importance (37). Nuclear grade has been shown to correlate 
with subsequent development of invasive carcinoma (36;42;43). In addition, the 
role of certain biological markers is being explored with respect to their 
association with high grade lesions and conferring increased risk of recurrence. 
Such markers include HER2, p53 and hormone expression and ploidy.
Such studies have emphasised the heterogeneity of DCIS by suggesting that some 
types of noncomedo DCIS must be seen as high grade either because of cytologic 
criteria or because they express some other markers with the same significance, 
such as immunoreactivity for HER2 and aneuploidy (44).
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1.4.2.1 The Van Nuys classification system of DCIS
Nuclear grade, comedo-type necrosis, tumour size, and the width of the tumour 
margin are all important predictors of the probability of local recurrence after 
breast conservation treatment for DCIS (36;37;39;43;45-47). Two of these factors, 
nuclear grade and necrosis, were used to develop a simple, reproducible 
classification called the Van Nuys classification (39). This classification yields 
three different subgroups of patients with DCIS, with different rates of local 
recurrence after breast conservation (39). The presence of any amount of high 
nuclear grade (nuclear grade 3) defines the most aggressive group. The remaining 
non-high-grade lesions (nuclear grades 1 or 2) are then divided by the presence 
(group 2) or absence (group 1) of comedo-type necrosis (Figure 5).
DCIS 
All types
High grade nuclei 
Group 3
Non-high grade nuclei 
with necrosis 
Group 2
Non-high grade nuclei 
without necrosis 
Group 1
Figure 5. The Van Nuys DCIS Classification system
A statistically significant risk of local recurrence was found; 7% for Group 1,16% 
for Group 2 and 39% for Group 3.
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Pathologic classification alone is insufficient for selecting appropriate treatment 
for patients with DCIS because it fails to take into account 2 additional significant 
predictors of local recurrence: tumour size and the histologic margin width after 
excision. The Van Nuys Prognostic Index was therefore developed to overcome 
this problem (see section 1.4.7.3).
1.4.2.2 The Nottingham Prognostic Index (NPI) for invasive breast cancer
In 1992 the NPI was first published as an attempt at using some fairly objective 
parameters to determine the odds that a newly diagnosed case of primary invasive 
breast cancer would benefit from adjuvant chemotherapy (48). The NPI uses a 
combination of size, nuclear grade and lymph node status to divide patients into 3 
groups, each of which have differing prognoses. The equation used to stratify 
patients is:
Nottingham prognostic index = (0.2 x size)+lymph node stage + grade 
where size is measured in centimeters; lymph node stage 1 is lymph node­
negative, stage 2 is one to three positive lymph nodes, stage 3 is >= four positive 
lymph nodes; and the scoring of histologic grade is 1 to 3.
The histologic grade used in this index was evaluated according to Elston and 
Ellis (49). The grading procedure consisted of judgment of tubule formation, 
nuclear pleomorphism, and mitotic count. The number of mitoses was counted in 
10 high-power fields, and the results were adjusted to the area of the microscopic 
field. Each of the three morphologic features; tubules, nuclear pleomorphism, and 
number of mitoses, was given a score of 1 to 3 points. The overall histologic 
grade was obtained by adding the score of each characteristic, giving a possible
total score of 3 to 9 points. The histologic grade allocation was as follows: grade 
1,3 to 5 points; grade 2 ,6  to 7 points; and grade 3,8 to 9 points.
The overall score then determines which group patients fall into as shown in Table 
1.
NPI Group 1 
(Score < 3.4)
NPI Group 2 
(Score 3.4-5.4)
NPI group 3 
(Score >5.4)
Need for 
chemotherapy
Need is doubtful
May benefit from 
chemotherapy
Chemotherapy
required
Table 1. The Nottingham Prognostic Index.
This index is widely though not universally used, as it requires the status of the 
axillary lymph nodes to be determined which is not routine practice in some 
centers. It is used in Glasgow to aid in management decisions regarding 
chemotherapy.
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1.4.3 Clinical and radiological presentation of DCIS
Prior to the advent of mass population screening, the commonest presentation of 
DCIS was a palpable mass. With mass screening programs and improvements in 
mammographic techniques, DCIS is most commonly picked up as a result of 
abnormalities seen on mammography (50). DCIS now accounts for up to 30% of 
newly diagnosed cases of breast cancer in centres offering screening 
mammography (51).
Microcalcifications are the most common mammographic appearance associated 
with DCIS. However, benign lesions also present as microcalcifications. Accurate 
characterisation and visualisation of calcifications is therefore essential to the 
correct diagnosis and usually requires magnification of mammographic imaging. 
The morphology of calcifications is generally considered to be the most important 
factor in distinguishing benign forms of calcification from malignant ones. 
Malignant calcifications are usually in the intraductal spaces of the lesion and 
appear faint, irregular, linear and often have branching distribution patterns. 
Heterogeneous clustered calcifications, fine linear branching calcifications, or 
calcifications in a segmental distribution are suggestive of malignancy. Figure 6 
shows the type of calcification seen in a case of comedo DCIS.
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D iffu se  intraductal
calcification
Figure 6. Calcification on mammography o f a case o f comedo type DCIS.
Benign calcifications often appear as random calcifications scattered throughout 
large volumes of breast tissue. Calcium sediment layering in cysts (milk of 
calcium), lucent centered calcifications o f fat necrosis, dermal calcifications, and 
solid, large rod-shaped secretory calcifications are indicative o f a benign lesion.
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Figure 7. Examples o f mammographic appearance o f benign calcifications. On 
the left are rod-like calcifications (identified by arrows) indicating benign 
secretory disease. On the right are “milk o f  calcium ” type calcifications.
Despite these differences and careful mammographic examination, calcifications 
frequently have an indeterminate appearance. In these circumstances tissue 
sampling using image directed procedures such as stereostactic needle core biopsy 
may be necessary.
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1.4.4 Natural history of DCIS
The natural history of any disease forms the basis for recommended treatments 
and assessments of outcome. Breast cancer is a heterogeneous group of tumours. 
The various pathological types are listed in Table 2. The natural history of breast 
cancer is normally characterized by long duration, but shows extreme variation 
between individual patients. In contrast to the well-defined successive progression 
of colorectal carcinoma from adenomas, there is no generally accepted natural 
history of breast cancer (52;53).
Approximate incidence (%)
In situ carcinoma 15-30
DCIS 80
LCIS 20
Invasive carcinoma 70-85
Ductal carcinoma (no special type) 79
Lobular carcinoma 10
Tubular / Cribriform carcinoma 6
Mucinous carcinoma 2
Medullary carcinoma 2
Papillary carcinoma 1
Table 2. Histologic types o f breast cancer (54).
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The best measures of the course of DCIS have been found in autopsy studies and 
in retrospective reviews of biopsies for what was originally thought to be benign 
disease and was later found to be DCIS.
There have been 7 major autopsy studies of women not known to have had breast 
cancer. Six of these found an incidence of DCIS of 4% to 18% (55). The largest of 
these studies showed a much lower incidence of DCIS at 0.2% (One case out of 
519) (15). However, this paper included a significant number of women from 
ethnic subgroups (Hispanic and American Indian) known to have a lower risk of 
developing breast cancer. This study also found that proliferative disease without 
atypia, atypical ductal hyperplasia and DCIS are progressively less frequent in the 
breasts of women dying from causes other than breast cancer (15). Only 1 case out 
of more than 1000 patients in these 7 studies was found to have invasive breast 
cancer.
The largest retrospective review, with adequate follow up, of breast biopsies 
which were originally thought to be benign and subsequently found to be 
malignant has come from Vanderbilt (56;57). On histologic review of slides from 
11 760 women in whom benign lesions had originally been diagnosed between 
1959 and 1968, 28 patients were identified as having DCIS lesions. These 
tumours were predominantly small, low grade, non-comedo type DCIS with 
uncertain surgical margins. Follow up was for an average of almost 30 years. Nine 
of these 28 women have gone on to develop invasive breast cancer in the same 
quadrant from which DCIS was originally biopsied, giving a rate of 32%. The first 
of these cases did not present until 15 years after the initial surgery. A further 
patient developed metastatic breast cancer over 30 years after the original biopsy.
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It is important to note that this series did not contain any cases of comedo type 
DCIS and that this may have been a factor in the long delay in the progression to 
invasive disease.
Other similar studies have yielded concurring results. Rosen and colleagues (58) 
reported on the long term follow up (average of 21.6 years) of 15 women in whom 
benign lesions were originally diagnosed. After a median of 9.7 years, 10 women 
had developed clinically apparent carcinoma in the ipsilateral breast with 4 of 
these having developed metastatic breast carcinoma. As with the Vanderbilt 
experience, these DCIS lesions were of the low grade type.
Eusibe and colleagues (59) also reported on 80 patients with a mean follow up of 
17.5 years with an original diagnosis of benign disease. They found that DCIS 
recurred in 5 patients (6%) and invasive carcinoma developed in 11 women 
(14%). The recurrence was ipsilateral in the majority of patients (11 of 16 
patients).
A striking feature of these studies is that the natural history of DCIS may take 
over 20 years to develop and that a patient not undergoing definitive treatment of 
even low grade lesions may still be at significant risk.
Our understanding of the preclinical phases of breast cancer is mainly based on 
indirect observations of the morphological changes from normal epithelium 
through a series of increasingly abnormal changes ranging from hyperplasia 
(proliferative disease without atypia), to atypical hyperplasia, to non-invasive 
carcinoma, to primary invasive carcinoma, and finally to metastatic carcinoma 
(60). Such observations include studies which show progressively increasing 
relative risks of later developing invasive breast cancer in women with previously
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excised proliferative disease without atypia (relative risk = 1.2-2.0), atypical 
ductal hyperplasia (relative risk = 4.0-6.0) and DCIS (relative risk = 10.0-12.0) 
(61-63). Other studies have observed that lesions such as proliferative disease 
without atypia, atypical ductal hyperplasia, and DCIS are concurrently observed 
in 50-90% of breasts containing invasive breast cancer (16;64). Progression 
through these stages is not inevitable and, in theory, stages may be missed out. It 
is also possible that a given stage may be permanent or may even regress towards 
normality. There are several reasons why our understanding of the natural history 
of DCIS is inconclusive:
1. It is likely that palpable DCIS detected before mass screening programmes 
had a different natural history to mammographically detected DCIS. Palpable 
lesions were more likely to have had larger areas of DCIS and more likely to 
have had undetected areas of invasion (65) compared to small impalpable 
DCIS detected as an area of microcalcification on mammography.
2. The traditional treatment of DCIS was mastectomy and therefore the natural 
history could not be studied.
3. Autopsy studies suggest that some but not all cases of DCIS progress to 
invasive disease.
4. Many treatment reports include data on patients with microinvasion which is 
therefore not true DCIS.
The obvious challenge in the study of DCIS and in managing patients with this 
condition lies in reliably identifying those at risk of a poor outcome and applying 
aggressive initial management while not subjecting those with a good outcome to 
the same, perhaps unnecessary, treatments.
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1.4.5 Multicentricity of DCIS
DCIS has in the past been thought to be a multicentric condition, i.e. it arises 
separately in different quadrants of the breast. This has been the rational for 
treating the disease by mastectomy thereby eliminating the risk to other parts of 
the breast and obtaining a “cure”. Studies supporting the theory of multicentricity 
have reported an incidence of multicentricity as high as 32% (65-70). Most of 
these studies were done in mastectomy specimens from patients who had 
previously had a biopsy for DCIS. Where cases had cancer cells remaining, these 
were considered as separate foci, which is clearly incorrect, and these lesions were 
therefore labelled as being multicentric.
Current theory is that most DCIS cases are not multicentric. Holland and 
colleagues found that of 82 mastectomy specimens from patients with DCIS, 
using subgross sectioning and extensive sampling, only one lesion was truly 
multicentric (71). They found that 23% of lesions extended over more than one 
breast quadrant and that mammographic estimations frequently underestimated 
the size of the lesions. This may be a factor in the finding that DCIS often recurs 
at or near the site of the original lesion (72). This is a crucial factor in determining 
the feasibility of breast conserving therapy because clearly resection of the 
affected area must involve a complete resection with clear margins.
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1.4.6 Treatment of DCIS
As would be expected with a lesion which is at worst preinvasive, a diagnosis of 
DCIS carries an excellent prognosis regardless of the surgical treatment chosen. A 
wide range of treatment plans have been developed to treat DCIS and this is partly 
the result of uncertainty regarding the natural history of the lesion and the lack of 
pathological standardisation between centres. The treatment and management of 
DCIS is today extremely controversial. The treatment options include:
1. local excision only
2. local excision plus radiotherapy
3. mastectomy
4. axillary staging
5. hormonal therapy
Current treatments for DCIS range from simple tumour excision, to various forms 
of wider excision such as quandrantectomy to mastectomy with or without 
reconstruction. All forms of treatment less than mastectomy may be followed by 
radiotherapy. As DCIS is a heterogeneous group of lesions and all patients are 
different with varying requirements and expectations, no single treatment 
approach is correct for all forms of the disease.
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1.4.6.1 Mastectomy
In the past, mastectomy was the standard treatment for DCIS in all its forms. 
Although this is clearly overtreatment for a large number of cases, it results in an 
extremely low local recurrence rate (0-5%) and mortality (0-2%) from breast 
cancer (5;45). The rationale for mastectomy included a 30% incidence of 
multicentric disease, a 40% prevalence of residual tumour at mastectomy 
following wide excision alone, and a 25-50% incidence of breast recurrence 
following limited surgery for a palpable tumour, with half of those recurrences 
being invasive carcinoma (65;73). Some of these reasons have now been 
disproved, such as multicentricity (see section 1.4.5).
The success of breast-conserving surgery for invasive carcinoma resulted in this 
approach being used in DCIS although no randomised trials comparing 
mastectomy to breast-conserving surgery with radiotherapy have been carried out. 
Many of the series evaluating mastectomy for the treatment of DCIS were carried 
out before mammography was widely used and were performed on patients with 
palpable disease or nipple discharge. Comparisons with more recent series of 
breast-conserving surgery containing patients with impalpable disease detected on 
mammography is therefore difficult.
The advantage of mastectomy is that it is an effective treatment which negates the 
need for close follow up of the ipsilateral breast. However, it will represent over­
treatment for the majority of patients given that many DCIS lesions will not 
progress to invasive cancer or cause death.
For selected patients with invasive breast carcinoma, breast-conserving surgery 
has proved to be as effective as mastectomy (74-77). It is therefore inconsistent
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that a non-invasive condition should be treated by more aggressive methods than 
an invasive breast cancer. However, mastectomy for DCIS almost invariably 
results in cure and it is a tragic situation where a woman develops metastatic 
disease from an invasive recurrence of a lesion that was non-invasive at the time 
of detection. Mastectomy remains the gold standard for treatment of DCIS against 
which other treatment modalities should be compared.
1.4.6.2 Breast-conserving surgery with radiotherapy
Reported series of breast-conserving surgery and radiotherapy show a reduction in 
the rate of local recurrence by the addition of radiotherapy (Table 3) (78-95). 
Local recurrence rates are reported at between 5% and 10%, with approximately 
50% of recurrences being invasive.
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Time
period
Authors
Number
of
patients
Median length of 
follow up (months)
Recurrence
Invasive 
recurrence (%)
No %
1955-1980 Montague et al(80) 34 NR 1 3 100
1958-1987 Stotter et al(95) 44 92 4 9 100
1967-1985 Fourquet et al(91) 67 104 7 10 71
1968-1990 Cataliotti et al(78) 34 50 3 9 100
1974-1988 Baird et al(84) 8 43* 2 25 50
1975-1987 Cutuli et al(79) 34 56 3 9 33
1975-1985 Kurtz et al(93) 43 61 3 7 100
1976-1978 Fisher et al(85) 27 83* 2 7 50
1976-1990 Ray et al(88) 58 61 5 9 20
1976-1990 Hiramatsu et al(83) 76 74 7 9 57
1977-1988 McCormick et al(94) 54 36 10 19 30
1978-1985 Solin et al(89) 51 68 5 10 40
1978-1985 Fowble(92) 46 35 2 4 NR
1979-1990 Silverstein et al(82) 103 63 10 10 50
1979-1987 Kuske et al(86) 70 48 3 4 100
1979-1991 Bullock et al(87) 43 62 3 7 33
1982-1988 White et al(90) 52 68 3 6 33
1985-1990 Fisher et al(81) 399 43* 28 7 29
Total number of patients: 1243 101
47.5 of 
recurrences
Table 3. Published studies o f the outcome o f treatment o f DCIS with breast- 
conserving surgery and radiotherapy. * mean; NR, not reported.
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A further collaborative study was published in 1995 involving 10 European and 
North American centres reporting follow up on 268 patients treated with breast- 
conserving surgery and radiotherapy with a median follow up of 10.3 years (96). 
The actuarial rate of local recurrence at 15 years was 20% and survival was 96%. 
This study suggests that, as is the case with invasive breast cancer, the rate of 
local recurrence of DCIS increases with time, either because new disease develops 
or residual DCIS progresses (36). A complicating factor of this study is that the 
surgical resection margins were not known for almost 50% of patients. As 
described in section 1.4.6.2, resections margins are an important factor 
determining the risk of local recurrence. With this fact now generally accepted, it 
is likely that future studies will show a further decrease in local recurrence for 
patients treated by breast-conserving surgery and radiotherapy.
In addition to the single institution studies described above, in the mid-1980’s two 
randomised controlled trials were started to find out whether breast-conserving 
surgery was a reasonable approach to the management of DCIS. These are 
described in the following sections.
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1.4.6.2a National Surgical Adjuvant Breast and Bowel Project (NSABP) 
study Protocol B-17 (97;98)
The results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
study Protocol B-17 were published in 1993 (97) and updated in 1995 (98) and 
1998 (97). This study randomly assigned 818 women with localised DCIS and 
negative surgical margins following excisional biopsy to breast irradiation with 50 
Gy or to no further therapy. In this study, 80% of patients were diagnosed by 
mammography and 70% had small lesions (1cm or less). Events were defined as 
the presence of new ipsilateral disease, contralateral disease, metastases, a second 
primary tumour or death from any cause. After 8 years of follow-up, the event- 
free survival for the irradiated patients was 75% compared to 62% for the non­
irradiated patients (p=0.00003). A significant decrease in local recurrence of 
DCIS and of invasive breast cancer was seen in patients treated with radiotherapy. 
The overall local recurrence rate for patients treated by excision alone was 27% at 
8 years. For patients treated with excision plus irradiation, it was 12% at 8 years 
(p=0.000005). Specifically, the occurrence of invasive breast cancer decreased 
from 13.4% to 3.9% with the addition of radiotherapy (p=0.001), and recurrent 
DCIS was reduced from 13.4% to 8.2% (p=0.007). The recommendations of the 
study were therefore for all patients with DCIS treated by breast-conserving 
surgery to have post-operative radiotherapy. These recommendations are thought 
to be too wide by many authors (99) and the study itself has been criticised for a 
number of reasons discussed below.
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1.4.6.2b The European Organisation for Research and Treatment of Cancer 
(EORTC) study (100)
The EORTC trial began and concluded after the NSABP trial and essentially 
supported the findings of the earlier study. The aim of the study was to investigate 
the role of radiotherapy after complete excision of DCIS. Between 1986 and 1996, 
1008 women with DCIS lesions measuring 5cm or less were randomly assigned to 
either no further treatment or to radiotherapy and followed up for a median of 4.25 
years. The 4-year local relapse-free was 84% in the group treated with local 
excision alone compared with 91% in the women treated by local excision plus 
radiotherapy (log rank p=0.005; hazard ratio 0.62). When the local relapses were 
classified as either DCIS or invasive carcinomas, there were approximately equal 
reductions by radiotherapy; a reduction of DCIS recurrence from 8% to 5% 
(hazard ratio = 0.65 [95% Cl 0.41-1.03]) and a reduction from 8% to 4% (hazard 
ratio = 0.60 [95% Cl 0.37-0.97]) of invasive carcinomas. Similar reductions in the 
risk of invasive (40%, p=0.04) and non-invasive (35%, p=0.06) local recurrence 
were therefore seen.
They conclude that the addition of radiotherapy after complete excision of DCIS 
reduced the overall number of both invasive and non-invasive recurrences in the 
ipsilateral breast at a median follow up of 4.25 years. They also stress the point 
that patients with an unacceptably high risk of local recurrence despite breast- 
conserving surgery plus radiotherapy need to be identified so that they can be 
offered mastectomy. Equally, patients with a very low risk of local recurrence and 
potentially very small benefit from radiotherapy should be identifiable so that 
unnecessary irradiation can be avoided.
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1.4.6.2c Criticism of NSABP Protocol B-17 and the EORTC study
The EORTC study was published in 2000, 2 years after the outcome data for the 
NSABP B-17 were published. The EORTC study design and definition of clear 
margin were essentially the same as the NSABP B-17 study. The overall 
reductions in local recurrence of DCIS were similar for the 2 trials (approximately 
50%) but there were differences in the rates of invasive local recurrence and 
contralateral breast cancer as discussed below (section 1.4.6.3).
The main criticism of the NSABP B-17 study was a lack of analysis of different 
subsets of DCIS and the lack of size measurements in more than 40% of cases in 
the initial report (101; 102). Other problems were the lack of requirement for 
mammographic-pathological correlation or of specimen radiography; the lack of 
uniform guidelines for tissue processing or of estimation of size of the lesions; 
possible inclusion of patients with atypical ductal hyperplasia; and the authors’ 
definition of what constitutes a clear margin. Margins were defined as clear when 
a tumour was not transected. Most investigators would now agree that local 
recurrences after lumpectomy for DCIS most likely reflect residual disease, (103- 
105) and that the acceptance of minimally clear margins of 1 mm. or less, is 
inadequate for local control.
The EORTC study is open to similar criticisms as the NSABP study (102; 106). 
There was no subset analysis giving comparative rates of local recurrence for 
various subgroups, such as high grade versus low grade; wide excision versus 
narrow margins; or presence of comedo type necrosis versus absence of this. At 
the time of publication there were too few recurrences in the EORTC trial for such 
subset analyses.
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In defence of these 2 studies, they were designed at a time when an important 
question in the treatment of DCIS was whether radiotherapy was beneficial to 
patients with DCIS treated by breast-conserving surgery. The studies did exactly 
what they were designed to do; i.e. to prove that radiotherapy was effective for 
patients with DCIS treated by breast-conserving surgery. However, by the time of 
publication of their results the important questions that needed answered and the 
understanding of DCIS as a disease had changed considerably. The questions 
asked now are more complex. We now want to know exactly which subgroups 
will benefit from radiotherapy and by how much. If the benefit is known to be 
small then the cost and complications of radiotherapy may deem it inappropriate.
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1.4.6.2d Is routine use of radiotherapy for DCIS treated by local excision 
justified?
The findings of the NSABP B-17 and the EORTC trials have encouraged 
clinicians to recommend radiotherapy for all patients with DCIS undergoing 
breast conserving surgery. Despite their data, there continues to be vigorous 
debate regarding the broadness of the recommendation that all such patients 
should undergo post-excisional radiotherapy.
A unique finding of the NSABP B-17 study was the 3.5 fold reduction (from 
13.4% to 3.9%) in invasive local recurrences after radiotherapy. Neither the 
EORTC nor any other study of breast conservation followed by radiotherapy has 
been able to support this finding. In the EORTC trial the reductions for DCIS and 
invasive recurrences were similar. The NSABP B-17 investigators have used the 
marked decrease in invasive local recurrence seen in their study as the main 
justification for recommending that all patients who have breast conservation 
surgery also have post-excisional radiotherapy. Although radiotherapy reduced the 
rate of local recurrence, neither of these 2 trials showed that post-operative 
radiotherapy had a beneficial effect on what should be considered the most 
important outcome variables: distant recurrences and breast cancer mortality. In 
both trials the rates for these variables were the same whether or not patients 
received radiotherapy.
The EORTC study found a potentially important increased rate of contralateral 
breast cancer in irradiated patients which reached statistical significance (p=0.01). 
The method of administering radiotherapy in this trial was to use a wedge or filter, 
which may have caused increased scatter of radiation to the contralateral breast. If
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this increased scatter proves to be the cause of the increased rate of contralateral 
breast cancer, it will decrease the relative value of a policy of indiscriminate 
radiotherapy in favour of a policy only for those patients who will benefit 
substantially from post-excisional radiotherapy.
Radiotherapy administration can cause significant side effects as well as having a 
substantial financial cost. Much of the information on the side effects of 
radiotherapy is confounded by treatment received decades ago with outmoded 
delivery techniques. Current delivery methods administer lower daily doses with 
field arrangements that limit exposure of normal tissue. These side effects include 
cardiac toxicity, development of second cancers, fatigue and radiation fibrosis of 
the breast, which can make mammographic follow up more difficult. While most 
of these effects such as cardiac toxicity are thankfully now very uncommon, it 
must be borne in mind that patients with DCIS are likely to live for a fairly long 
time. The effects of treatment are therefore with them for a long time and some of 
these may not as yet be apparent.
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1.4.6.3 Breast-conserving surgery alone
The potential benefits of breast-conserving surgery are that it allows preservation 
of the breast and it avoids the costs, inconvenience and potential toxicity of 
radiotherapy. The main disadvantage compared to mastectomy or breast- 
conserving surgery with radiotherapy is an increased risk of local recurrence, 
which if invasive has potential to progress to metastatic disease and death. 
Published series of DCIS treated by breast-conserving surgery alone are presented 
in Table 4 (37;43;69;78;81;82;84-86;107-114). Despite careful patient selection, 
recurrence rates approach 20% after relatively short follow up. An equal 
proportion of invasive and DCIS recurrences occur. Lagios et al (37) reported that 
DCIS lesions less than 2.5cm with clear margins had a local recurrence rate of 
10% after a mean follow up of 44 months. As with invasive breast cancer, this 
figure is likely to increase with longer follow up. In a similar study, Bellamy et al 
(43) reported a recurrence rate of 30% for 31 patients at 60 months follow up 
where the re-excision margins were clear.
Survival rates after treatment of DCIS with breast-conserving surgery alone of 98- 
100% albeit after short follow up is similar to those reported for mastectomy and 
for breast-conserving surgery with radiotherapy. The disadvantage lies in the 
significantly higher rates (approaching 20%) of local recurrence which puts 
patients at a higher risk of potentially incurable invasive recurrence of 10% and an 
equal 10% risk of recurrent DCIS. Recurrent DCIS can potentially be cured by 
salvage mastectomy but invasive recurrence is potentially incurable and in a 
proportion of patients will result in metastatic disease. The precise indications for
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breast-conserving surgery alone will be best determined by prospective 
randomised clinical trials.
Time
period
Authors
Number
of
patients
Median length of 
follow up (months)
Recurrence
Invasive 
recurrence (%)
No %
1944-1981
Gallagher et al 
(113)
13 100 5 38 60
1948-1968
Millis and Thynne 
(111)
8 24-180§ 2 25 0
1949-1967 Farrow (110) 25 NR 5 20 0
1953-1984 Temple et al (107) 17 72 2 12 50
1968-1990 Cataliotti et al (78) 46 70 5 11 100
1972-1982 Price et al (112) 35 108 22 63 55
1972-1987 Lagios et al (37) 79 44 8 10 50
1974-1988 Baird et al (84) 30 43* 4 13 25
1974-1989 Bellamy et al (43) 31 60 10 32 50
1976-1978 Fisher et al (85) 21 83* 9 43 56
1978-1984 Amesson et al(109) 38 60 5 13 20
1978-1990 Schwartz et al (69) 72 49* 11 15 27
1979-1986
Carpenter et al 
(108)
28 38 5 18 20
1979-1987 Kuske et al (86) 7 48 3 43 33
1979-1990 Silverstein et al(82) 26 19 2 8 50
1982-1987 Ottesen et al (114) 112 53 25 22 20
1985-1990 Fisher et al (81) 391 43* 64 16 50
Total number of patients: 979 187
42.7% of 
recurrences
Table 4. Published studies o f the outcome o f treatment o f DCIS with breast-
conserving surgery alone. * mean; NR, not reported. § range
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1.4.6.4 The axilla
There is now uniform agreement that for true DCIS there is no indication for 
treatment to the axilla (115;116). The incidence of lymph node metastases in 
DCIS is negligible (<1%) (117-119). In a study published in 1994, Silverstein and 
colleagues examined 200 axillary lymph node dissections for patients with DCIS 
without evidence of microinvasion (120). None of the cases examined had 
involved lymph nodes. This is perhaps not surprising in true in situ disease, 
however it can prove impossible to identify a small focus of invasion in a large 
area of DCIS. The challenge for pathologists lies in identifying those cases of true 
DCIS without evidence of microinvasion and therefore no potential for 
metastasising. The risk of having foci of microinvasion in DCIS appears to be 
directly proportional to the size of the lesion. In a study published in 1989 Lagios 
and colleagues (37) analysed 115 specimens for microinvasion by using 
intraoperative radiography and careful sequential sectioning at 2-3mm. intervals. 
The overall rate of microinvasion was 14.7% (Table 5). This evidence is even 
more convincing as all 4 lesions less than 35mm which showed evidence of 
microinvasion were thought to have inadequate localisation biopsies and that an 
adequate biopsy would have revealed invasive disease and the patients therefore 
excluded from this study.
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Size of DCIS lesion (mm) Incidence of microinvasionNo/Total %
<25 1/60 1.6%
26-35 3/15 20%
36-45 0/9 0%
46-55 1/6 16.7%
>55 12/25 48%
Table 5. Incidence o f microinvasion in relation to the size o f the DCIS lesion. The 
rate o f microinvasion appears to have a direct relationship to the size o f the DCIS 
lesion.
1.4.6.5 The role of Tamoxifen
Tamoxifen has been shown in animal studies to have anti-initiator and anti­
promoter properties (121; 122). It has also been shown to prevent tumour 
recurrences in the ipsilateral breast and second primary tumours in the 
contralateral breast of women who have undergone lumpectomy and radiotherapy 
for primary invasive breast cancer (123; 124). This suggests that tamoxifen can 
interfere with development of primary invasive breast cancer from the start or 
with the progression of DCIS to invasive cancer. The NSABP B-24 trial (125) 
was set up to investigate whether or not tamoxifen was effective in reducing 
recurrences of DCIS or invasive cancer when used in conjunction with breast- 
conserving surgery followed by radiotherapy. In this study, following breast- 
conserving surgery and radiotherapy for DCIS or DCIS with LCIS, 1804 women
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were randomised to receive either placebo or tamoxifen 20mg per day for 5 years. 
Follow up was for a median of 74 months. Patients with positive resection 
margins were included. The addition of tamoxifen resulted in a statistically 
significant 44% decrease in development of invasive breast cancer in the 
ipsilateral breast (p = 0.004) and a 37% decrease in the contralateral breast which 
was not statistically significant (p = 0.22). The rate of ipsilateral non-invasive 
tumours was not significantly lower in the tamoxifen group (18% reduction, p = 
0.43). The rate of contralateral non-invasive tumours in the tamoxifen group was 
significant although the numbers were small (13 vs. 3, 78% reduction, p = 0.02). 
These findings suggest that the addition of tamoxifen is beneficial to women 
treated by breast-conserving surgery and radiotherapy. The advantage appears 
mainly to be in a decrease in the rate of invasive cancer especially in the 
ipsilateral breast. When events occurring in the contralateral breast and at regional 
and distant sites are included, there is a significantly lower rate and cumulative 
incidence of all breast cancer related events than in the no tamoxifen group.
In addition to this study there is a United Kingdom DCIS trial (UKCCCR-DCIS 
Phase III-90001) evaluating tamoxifen in DCIS which is as yet unpublished.
While tamoxifen appears to be effective at preventing contralateral breast cancer 
and reducing local recurrence in patients with DCIS undergoing breast 
conservation treatment it does have significant side effects. In premenopausal 
patients it may cause menopausal symptoms including hot flushes, vaginal 
discharge and irregular menses. In this group of patients it may also cause an 
increase in bone loss due to its oestrogen antagonist activity (126). In 
postmenopausal patients, tamoxifen therapy is associated with an approximate
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doubling of the risk of endometrial cancer (127-129), especially in women over 
the age of 50. There is also a slightly increased risk of deep vein thrombosis and 
pulmonary embolism (127; 128). Tamoxifen does preserve bone mineral density in 
postmenopausal women (130) but whether it reduces the risk of vertebral or hip 
fractures is uncertain. Obviously, the risks and benefits of tamoxifen therapy 
should be discussed with each patient on an individual basis.
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1.4.7 Risk factors for recurrence of DCIS.
1.4.7.1 Nuclear grade
In the 1980’s Lagios drew attention to the value of nuclear grade and necrosis as 
predictors of disease recurrence following wide excision of DCIS (37;42). In 
earlier studies (37;42), Lagios reported a scheme for classifying DCIS based on 
architectural features, nuclear grade and tumour necrosis. Nuclear grade was 
found to be the strongest predictor of recurrence with 9 of 36 (25%) high nuclear 
grade lesions recurring compared to 1 of 43 (0.02%) of intermediate or low 
nuclear grade lesions. In a subsequent study (131) in which the Lagios system was 
used high grade DCIS was associated with a local recurrence rate of 32% 
compared to 10% for intermediate grade and 0% for low grade. This has 
subsequently been supported by several studies (38-40;43;132).
Nuclear grade is now a component of most classification systems for DCIS, 
including the European Pathologists’ Working Group (38) (nuclear grade and cell 
polarisation), the Nottingham Classification (40) (nuclear grade, necrosis and 
morphology) and the Van Nuys Classification System (39) (nuclear grade and 
necrosis). The European Breast Screening Working Groups (19) uses a system 
which has been adopted by the UK National Coordinating Group for Breast 
Screening Pathology and the European Working Group for Breast Screening 
Pathology and consequently is the classification recommended in the pathology 
guidelines for the NHS Breast Screening Programme and the EC Breast Screening 
Network. This system is based solely on nuclear grade.
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1.4.7.2 Resection margins
There is now general agreement that tumour margins should be assessed 
adequately before a treatment option is confirmed. However, there is no consensus 
on what constitutes an adequate margin following breast-conserving surgery. 
Most recurrences in patients treated by breast-conserving surgery or breast- 
conserving surgery and radiotherapy occur in the immediate area of the original 
excision site which suggests that the recurrences arise from incomplete surgical 
removal rather than from separate areas of DCIS (82;88;89;91;93;133-135).
In those retrospective series where an attempt has been made at assessing margins, 
a clear margin has been accepted as the absence of tumour cells at the inked 
resection margin. These series include those reported by Gallagher et al (113) 
(recurrence rate 38.5%) and Lagios et al (37) (recurrence rate 10%). However, 
NSABP (B-06) trial showed this to be unacceptable for treating patients by 
lumpectomy alone: patients treated by lumpectomy alone with ‘clear’ margins had 
a local recurrence rate of 43% (85). The pathological assessment of the NSABP 
(B-17) trial showed that the most significant predictor for local recurrence was the 
presence of a margin that was either involved or uncertain (98). A further study by 
Amesson et al (109) reported recurrence rates of 38% when margins were <5mm 
and 6% when margins were >5mm. The Nottingham group have adopted a policy 
of resecting a cylinder of tissue from skin to the pectoral fascia with a minimum 
margin of 10mm. Since adopting this policy, 1 of 48 patients has had a recurrence 
of DCIS after follow up of 45 months (136). Histopathologic mapping studies of 
DCIS lesions have shown that gaps of normal duct epithelium exist between foci 
of DCIS. In a study by Faverley et al (137), they reported on a 3-dimensional
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study of DCIS in 60 mastectomy specimens. Continuous and multifocal growth 
patterns were usual, and that multicentric tumours (defined as a gap of 4cm or 
more) are rare, occurring in only 1 case. Poorly differentiated tumours more often 
had continuous growth, whereas well differentiated tumours had multifocal 
distribution. Low grade lesions have more gaps than high grade lesions but only 
8% of all gaps were more than 10mm and 7% were in well differentiated tumours. 
This implies that leaving a 10mm margin is likely to result in lower rates of local 
recurrence, as DCIS is a contiguous process in the majority of cases (138).
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1.4.7.3 Van Nuys Prognostic Index (VNPI) (139)
The VNPI was devised by combining 3 statistically significant predictors of local 
tumour recurrence in patients with DCIS: tumour size, margin width and 
pathological classification. A score ranging from 1 for lesions with the best 
prognosis to 3 for the worst prognosis was assigned for each of the 3 predictors as 
described in Table 6 below.
Size score:
1 15mm or less
2 16-40mm
3 41mm or more
Margin score:
1 10mm or more
2 l-9mm
3 Less than 1mm
Pathological 
classification score:
1 Group 1 (non high grade lesions without necrosis)
2 Group 2 (non high grade lesions with necrosis)
3 Group 3 (all high grade lesions)
Table 6. Scoring system for the Van Nuys Prognostic System.
When these 3 scores are summed a prognostic value ranging from 3 to 9 is 
obtained (the Van Nuys Prognostic Index). The best possible score is 3 and the 
worst is 9. The VNPI was tested on 333 patients treated with breast-conserving 
surgery alone or breast-conserving surgery and radiotherapy. Table 7 summarises 
the results.
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VNPI score 3 or 4 5,6 or 7 8 or 9
8-year actuarial local recurrence free 
survival rate (%) 97 77 20
8-year actuarial breast cancer specific 
survival rate (%) 100 97 100
Treatment recommendation
Breast-
conserving
surgery
alone
Breast- 
conserving 
surgery & 
radiotherapy
Mastectomy
Table 7. Local recurrence rates and treatment recommendations based on the 
VNPI.
Patients with VNPI scores of 3 or 4 did not show a disease-free survival benefit 
from radiotherapy (100% vs. 97%). Patients with intermediate VNPI scores of 5, 6 
or 7 benefited from radiotherapy (85% vs. 68%; p = 0.017). Patients with a VNPI 
of 8 or 9 also benefited from radiotherapy (36% vs. 0%); p = 0.026), although the 
risk of recurrence is so high with or without radiotherapy that mastectomy should 
be considered.
The VNPI is an attempt to quantify known important prognostic factors in DCIS, 
making them clinically useful in the treatment decision making process. Although 
there is an obvious treatment choice for each group, the VNPI is a guideline which 
acts as a starting place for discussion with patients.
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1.4.8 Summary of treatment of DCIS
As with most forms of cancer treatment each case should be considered 
individually and treatment tailored to the individual’s tumour characteristics, 
general health and overall expectations. A reasonable management plan is given 
below:
Mastectomy may be appropriate if:
• the lesion is extensive (more than 5cm diameter of calcification on 
mammogram)
• margins still show DCIS after 2 attempts at wide local excision
• the initial lesion did not have calcification on mammography
• personal choice for any size or type of lesion 
Breast-conserving surgery and radiotherapy may be appropriate if the lesion:
• is l-5cm in diameter
• is high grade
• has a <1 Omm clear margin
Breast-conserving surgery alone may be appropriate if the lesion:
• is <15mm diameter
• is low grade
• has normal ducts between the lesion and the inked margins
• has a > 1 Omm clear margin
Although the treatment of DCIS remains a controversial area, this is clearly 
because our goals and the expectations of patients have become higher. The days 
when mastectomy was routine for all types of DCIS, including its most benign
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forms, are thankfully over. The challenge now lies in providing appropriate 
treatment tailored to each lesion and to each patient. Adequate diagnosis and 
treatment continue to require a multi-disciplinary approach involving surgeons, 
radiologists, pathologists, radiation oncologists and medical oncologists. Our 
understanding of the disease and our ability to better subclassify this disease will 
be helped by a better understanding of the role of various markers, including 
HER2 and other members of the Type 1 growth factor receptor family as well as 
p53 and hormone expression, DNA-ploidy and S-phase fraction, and perhaps 
other markers as yet undiscovered.
46
SECTION 2 CELL CYCLE CONTROL
2.1 Oncogenes
Oncogenes are genes that have been implicated in the formation of tumours. They 
are derived from protooncogenes, which are cellular genes that control normal 
growth and differentiation. These cellular genes were first discovered within the 
genome of acute transforming retroviruses, by the Nobel Laureates Varmus and 
Bishop (134), but are now known to be viral (y-onc) or cellular (c-onc). These 
protooncogenes can become oncogenic by retroviral transduction or by influences 
that alter their behaviour in situ, thereby converting them into cellular oncogenes. 
Oncogenes encode proteins (oncoproteins) which resemble the normal products of 
protooncogenes, with the exception that oncoproteins are devoid of important 
regulatory elements and their production in the transformed cells does not depend 
on growth factors or other external signals. The result is, therefore, excessive cell 
multiplication which may lead to malignant transformation. The discovery that 
certain oncogene products showed high amino acid sequence homology to 
components of growth factor signal transduction pathways triggered intense 
efforts to further define the role of growth factors in carcinogenesis. Although 
viruses are primarily associated with tumourigenesis in animals, some human 
examples are shown in Table 8.
Disease Virus
Cervical cancer Papilloma virus (HPV 16,18,31)
Nasopharyngeal cancer Epstein-Barr virus
T-cell leukaemia HTLV
Kaposi sarcoma Human Herpes Virus (HHV 8)
Table 8. Examples o f viruses associated with tumourigenesis in humans
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2.2 The Cell Cycle 
O -  cyclin Gi = growth and
preparation of the
Figure 8. The cell cycle
degraded
cyclins
► G o  chromosomes for
replication
CDK = Cyclin dependent 
kinase
Go = Resting phase
M = Mitosis
S = synthesis o f DNA (and 
centrioles)
G 2 = preparation for
A eukaryotic cell cannot divide unless two processes alternate: doubling of its 
genome (DNA) in S phase (synthesis phase) of the cell cycle and halving of that 
genome during mitosis (M phase). The period between M and S is called Gi; that 
between S and M is G2 .
Progression through each of the four distinct phases (Gj, S, G2 and M) is carefully 
controlled by the sequential formation, activation and subsequent degradation or 
modification of a series of cyclins and their partners, the cyclin-dependent kinases 
(CDKs). In addition, a further group of proteins, the cyclin-dependent kinase 
inhibitors (CDKIs) are important for coordination of each stage. The transition 
from one stage to the next is regulated at a number of checkpoints which prevent 
premature entry into the next phase of the cycle. The degradation o f various 
cyclins occurs at each checkpoint and it is this mechanism together with 
interaction o f the CDKIs and CDKs which allows the cell to enter the next phase.
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2.3 Protooncogenes
The roles of many cellular protooncogenes have now been elucidated. There are 4 
broad classes: -
a) Secreted growth factors
These exist as polypeptides, oligopeptides or steroid hormones. They bind to then- 
own specific receptors or, occasionally cross-react with several receptors, to 
stimulate or inhibit cell growth acting via a number of pathways leading to 
alterations in gene expression. Some stimulate growth by advancing the cell from 
Go to Gj, for example epidermal growth factor (EGF), platelet derived growth 
factor (PDGF) and fibroblast growth factor (FGF), or by aiding progression 
through Gi, for example insulin like growth factor. In contrast transforming 
growth factor p (TGFP) acts as an anti-mitogen by reversibly inhibiting cells at 
Gi.
b) Cell surface receptors
These bind a specific growth factor outside the cell. The receptor recognises the 
growth factor binding and sends a signal to within the cell. The transmembrane 
receptor tyrosine kinases are the most important of the growth factor receptors 
with respect to malignant transformation. As described below, these include the 
Type 1 Growth Factor Receptor family.
c) Components of intracellular signal transduction
Signal transducers act as proteins which transmit signals from a receptor to their 
cellular target. This is the largest class of oncogenes.
d) DNA-binding nuclear proteins, including transcription factors
This is the final site of action for messages sent from the growth factors and is the 
level at which control of growth and proliferation ultimately operates. The
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proteins either bind to specific DNA sequences exerting an immediate effect or 
form complexes which in turn bind to DNA. The activity of these transcription 
factors is regulated by phosphorylation.
2.4 Mechanisms of oncogene activation
a) Structural alteration
Point mutations have been described in several protooncogenes, especially in 
genes of the ras family of signal transducer proteins. Amino acid substitutions 
have been detected particularly at positions 12, 13 and 61. This results in the 
protein having reduced GTPase activity preventing deactivation of the active ras- 
GTP complex. This in turn leads to prolonged stimulation of signals from growth 
factor receptors.
Chromosomal translocation can create novel fusion proteins. The best known 
rearrangement produces the Philadelphia chromosome in chronic myeloid 
leukaemia (CML) where part of chromosome 9 is translocated to chromosome 22. 
This places the ABL oncogene on chromosome 9 next to the breakpoint cluster 
region (BCR) of the Philadelphia gene on chromosome 22 creating a novel fusion 
gene. The novel gene product has enhanced tyrosine kinase activity resulting in 
transforming properties.
b) Amplification
Many cancer cells contain multiple copies of structurally normal protooncogenes, 
for example, some breast cancers amplify HER2. Hundreds of extra copies may 
be present and can exist as small separate chromosomes (double minutes) or as 
insertions within normal chromosomes (homogeneously staining regions, HSRs) 
(135). This may lead to a very large overexpression of the gene product.
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Loss of appropriate control mechanisms.
Chromosomal translocation. Cellular oncogenes may show loss of normal 
transcription control through chromosomal translocation, for example, in Burkitt’s 
Lymphoma. Following the translocation of the myc protooncogene on 
chromosome 8 to one of the immunoglobulin heavy chain loci on chromosome 14 
(75-80% of patients), chromosome 2 or 22, there is constitutive overexpression of 
the transposed myc gene. This leads to over-production of the gene product 
resulting in a continuous stimulus for cell proliferation.
Insertional mutagenesis. Retroviruses can activate protooncogenes by insertional 
mutagenesis. The insertion of a DNA copy of the retrovirus into the cellular 
genome close to a protooncogene can cause abnormal activation of that gene by 
stimulation of gene expression via the promoter action of the retrovirus. The gene 
is then dysregulated from normal control mechanisms.
A specific oncogene may be activated by a variety of mechanisms and there is no 
single consistent mechanism of activation of a specific oncogene. In addition, 
multiple oncogenic mutations may occur within each specific tumour.
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SECTION 3 GROWTH FACTOR RECEPTORS IN BREAST CANCER
3.1 Growth factors and growth factor receptors
Growth factors are small polypeptides that are involved in the stimulation and also 
inhibition of cellular proliferation. Polypeptide growth factors mediate their 
actions by binding to cell surface proteins (receptors), which are thereby activated 
and ‘transduce’ the signal within the cell cytoplasm to the cell nucleus. Growth 
factor-induced changes in cellular status are multistage processes. Induction of 
growth factor synthesis, delivery to the target cell and the response of the cell 
itself all play a role in growth factor action. In many transformed tissues, 
particularly hormonally responsive tumours (breast, ovarian and endometrial 
cancers), steroid or other hormones may regulate tumour growth factor 
production. Once synthesized, growth factors act by endocrine, paracrine and 
autocrine mechanisms to affect cellular function. In some cases extemalization 
and release of growth factors may not be required for signaling to take place. 
Interactions between growth factors and receptors, either while both are anchored 
in the cell membrane (juxtacrine regulation), or even while both are still within 
the cell cytoplasm (intracrine regulation) have been postulated to explain some of 
the interactions seen between growth factors with transmembrane domains 
(juxtacrine) or those lacking sequences required for cellular release (intracrine). A 
feature of many transformed cells is the acquisition of autocrine growth control, 
mediated by tumour cells producing their own growth factors, which releases 
them from normal physiological regulators of proliferation.
Similarities in structure or function of many of the growth factors and their 
receptors have led to a classification of the majority of receptors into families and
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subclasses. Three major divisions of growth factor receptors have been identified, 
based on the primary mechanisms by which they mediate their effects. Growth 
factors attach to the ligand binding sites of growth factor receptors and the signal 
is mediated either by the intracellular domain or proteins associated with the 
receptor within the cell. This is the start of ‘signal transduction’ (140-142). Signal 
transduction mechanisms involve many diverse biochemical changes, but the 
initial event is usually clearly identifiable for any particular receptor family. Thus, 
this event is used to classify receptors into subclasses. For many receptors the 
initial signalling event that occurs following ligand binding is the activation of a 
kinase. Kinases induce phosphorylation of specific sites in target proteins. This 
phosphorylation causes marked changes in the conformation and activity of such 
targets often initiating a cascade of events leading to modification of cellular 
proteins and activation of nuclear transcription factors which initiate the synthesis 
of new proteins.
• Type I growth factor receptors (Tyrosine kinase receptors)
The epidermal growth factor receptor (EGFR) and the HER2 receptor are part 
of this family of receptors. A detailed account of this family of receptors is 
given in section 3.2. As their name implies these receptors initiate signaling 
by phosphorylation of tyrosine residues within the receptor.
• Type II growth factor receptors (Serine-threonine kinase receptors)
As with tyrosine kinase receptors the signalling event mediated by this class of 
receptors involves phosphorylation of serine and threonine residues within the 
receptor. Included in this group is the ras superfamily of signal transducer 
proteins. The active ras form activates a cascade of serine/threonine protein
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kinases controlling cell growth and differentiation, ras mutations are the 
commonest oncogenic abnormalities found in tumours, being present in -20% 
of tumours.
• Type III growth factor receptors (G-protein-linked receptors or 
seven-transmembrane receptors)
These are the most common type of growth factor receptor. These receptors 
mediate their action by association with a family of adenyl cyclase and kinase 
regulating proteins via an intermediary -  the G protein (guanine nucleotide 
binding protein). All G-protein coupled receptors have 7 transmembrane 
spanning regions. Activation of the receptor leads to inactivation of these 
regulatory proteins and subsequent inactivation of intracellular signal 
pathways (140).
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3.2 Type I growth factor receptors
3.2.1 Characteristics of type I growth factor receptors
It has been known for over 30 years that EGFR is expressed in breast tissue where 
it plays a role in mitogenesis and differentiation. EGFR was the first type I growth 
factor receptor to be cloned (143). It showed considerable homology to the avian 
erythroblastosis virus transforming protein, v-erbB. Following the pioneering 
work of Cohen and colleagues, this receptor has served as a prototype for the 
understanding of tyrosine kinase signalling, receptor dimerization, and signal 
transduction cascades. The mutation or amplification of this gene can convert its 
cognate protein to a form that confers increased cancer risk on experimental 
animals and humans. The EGF family (i.e. ligands binding to the EGFR) now 
includes transforming growth factor alpha, amphiregulin, heparin-binding EGF,^- 
cellulin, the heregulins, cripto-1 and certain viral-encoded proteins.
To date, three other family members of this growth factor family have been 
identified: HER2 (144-146), c-erbB-3 (147;148) and c-erbB-4 (149). These three 
receptors are also known as HER2, HER3 and HER4 (Human Epidermal Growth 
Factor Eeceptor). (The last 2 members of this family will not be considered 
further in this work as they do not form any part of this study).
These receptor proteins have a common structure consisting of an extracellular 
domain, a transmembrane region, a short juxtamembrane sequence and a 
cytoplasmic domain. The extracellular domain is the ligand-binding area and 
contains two cysteine rich regions. The cytoplasmic domain consists of a tyrosine 
kinase domain and a carboxyl-terminal tail that contains the mapped
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autophosphorylation sites (150; 151). A schematic diagram of this receptor family 
is shown in Figure 9.
The generally accepted mechanism of receptor activation is as follows: binding of 
ligand promotes receptor dimerization which increases the activity of the tyrosine 
kinase. This leads to specific tyrosine residues in the C-terminal tail becoming 
phosphorylated which then appear to serve as docking sites for molecules 
involved in signal transduction. Such molecules may be either substrates for the 
receptor tyrosine kinase or adaptor proteins involved in recruiting further proteins 
to the activated complex (152).
Study of this receptor family has resulted in critical insights into regulation of the 
normal mammary gland, in identification of one of the most commonly activated 
oncogenes in breast cancer (HER2), in recognition of critical mechanisms of 
breast tumour production, in identification of mechanisms of immune surveillance 
of breast cancer and in new ideas for drug therapy of the disease.
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2.3 Protooncogenes
The roles of many cellular protooncogenes have now been elucidated. There are 4 
broad classes: -
a) Secreted growth factors
These exist as polypeptides, oligopeptides or steroid hormones. They bind to their 
own specific receptors or, occasionally cross-react with several receptors, to 
stimulate or inhibit cell growth acting via a number of pathways leading to 
alterations in gene expression. Some stimulate growth by advancing the cell from 
Go to Gi, for example epidermal growth factor (EGF), platelet derived growth 
factor (PDGF) and fibroblast growth factor (FGF), or by aiding progression 
through Gi, for example insulin like growth factor. In contrast transforming 
growth factor P (TGFP) acts as an anti-mitogen by reversibly inhibiting cells at 
Gi.
b) Cell surface receptors
These bind a specific growth factor outside the cell. The receptor recognises the 
growth factor binding and sends a signal to within the cell. The transmembrane 
receptor tyrosine kinases are the most important of the growth factor receptors 
with respect to malignant transformation. As described below, these include the 
Type 1 Growth Factor Receptor family.
c) Components of intracellular signal transduction
Signal transducers act as proteins which transmit signals from a receptor to their 
cellular target. This is the largest class of oncogenes.
d) DNA-binding nuclear proteins, including transcription factors
This is the final site of action for messages sent from the growth factors and is the 
level at which control of growth and proliferation ultimately operates. The
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proteins either bind to specific DNA sequences exerting an immediate effect or 
form complexes which in turn bind to DNA. The activity of these transcription 
factors is regulated by phosphorylation.
2.4 Mechanisms of oncogene activation
a) Structural alteration
Point mutations have been described in several protooncogenes, especially in 
genes of the ras family of signal transducer proteins. Amino acid substitutions 
have been detected particularly at positions 12, 13 and 61. This results in the 
protein having reduced GTPase activity preventing deactivation of the active ras- 
GTP complex. This in turn leads to prolonged stimulation of signals from growth 
factor receptors.
Chromosomal translocation can create novel fusion proteins. The best known 
rearrangement produces the Philadelphia chromosome in chronic myeloid 
leukaemia (CML) where part of chromosome 9 is translocated to chromosome 22. 
This places the ABL oncogene on chromosome 9 next to the breakpoint cluster 
region (BCR) of the Philadelphia gene on chromosome 22 creating a novel fusion 
gene. The novel gene product has enhanced tyrosine kinase activity resulting in 
transforming properties.
b) Amplification
Many cancer cells contain multiple copies of structurally normal protooncogenes, 
for example, some breast cancers amplify HER2. Hundreds of extra copies may 
be present and can exist as small separate chromosomes (double minutes) or as 
insertions within normal chromosomes (homogeneously staining regions, HSRs) 
(135). This may lead to a very large overexpression of the gene product.
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Loss of appropriate control mechanisms.
Chromosomal translocation. Cellular oncogenes may show loss of normal 
transcription control through chromosomal translocation, for example, in Burkitt’s 
Lymphoma. Following the translocation of the myc protooncogene on 
chromosome 8 to one of the immunoglobulin heavy chain loci on chromosome 14 
(75-80% of patients), chromosome 2 or 22, there is constitutive overexpression of 
the transposed myc gene. This leads to over-production of the gene product 
resulting in a continuous stimulus for cell proliferation.
Insertional mutagenesis. Retroviruses can activate protooncogenes by insertional 
mutagenesis. The insertion of a DNA copy of the retrovirus into the cellular 
genome close to a protooncogene can cause abnormal activation of that gene by 
stimulation of gene expression via the promoter action of the retrovirus. The gene 
is then dysregulated from normal control mechanisms.
A specific oncogene may be activated by a variety of mechanisms and there is no 
single consistent mechanism of activation of a specific oncogene. In addition, 
multiple oncogenic mutations may occur within each specific tumour.
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SECTION 3 GROWTH FACTOR RECEPTORS IN BREAST CANCER
3.1 Growth factors and growth factor receptors
Growth factors are small polypeptides that are involved in the stimulation and also 
inhibition of cellular proliferation. Polypeptide growth factors mediate their 
actions by binding to cell surface proteins (receptors), which are thereby activated 
and ‘transduce’ the signal within the cell cytoplasm to the cell nucleus. Growth 
factor-induced changes in cellular status are multistage processes. Induction of 
growth factor synthesis, delivery to the target cell and the response of the cell 
itself all play a role in growth factor action. In many transformed tissues, 
particularly hormonally responsive tumours (breast, ovarian and endometrial 
cancers), steroid or other hormones may regulate tumour growth factor 
production. Once synthesized, growth factors act by endocrine, paracrine and 
autocrine mechanisms to affect cellular function. In some cases extemalization 
and release of growth factors may not be required for signaling to take place. 
Interactions between growth factors and receptors, either while both are anchored 
in the cell membrane (juxtacrine regulation), or even while both are still within 
the cell cytoplasm (intracrine regulation) have been postulated to explain some of 
the interactions seen between growth factors with transmembrane domains 
(juxtacrine) or those lacking sequences required for cellular release (intracrine). A 
feature of many transformed cells is the acquisition of autocrine growth control, 
mediated by tumour cells producing their own growth factors, which releases 
them from normal physiological regulators of proliferation.
Similarities in structure or function of many of the growth factors and their 
receptors have led to a classification of the majority of receptors into families and
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subclasses. Three major divisions of growth factor receptors have been identified, 
based on the primary mechanisms by which they mediate their effects. Growth 
factors attach to the ligand binding sites of growth factor receptors and the signal 
is mediated either by the intracellular domain or proteins associated with the 
receptor within the cell. This is the start of ‘signal transduction’ (140-142). Signal 
transduction mechanisms involve many diverse biochemical changes, but the 
initial event is usually clearly identifiable for any particular receptor family. Thus, 
this event is used to classify receptors into subclasses. For many receptors the 
initial signalling event that occurs following ligand binding is the activation of a 
kinase. Kinases induce phosphorylation of specific sites in target proteins. This 
phosphorylation causes marked changes in the conformation and activity of such 
targets often initiating a cascade of events leading to modification of cellular 
proteins and activation of nuclear transcription factors which initiate the synthesis 
of new proteins.
• Type I growth factor receptors (Tyrosine kinase receptors)
The epidermal growth factor receptor (EGFR) and the HER2 receptor are part 
of this family of receptors. A detailed account of this family of receptors is 
given in section 3.2. As their name implies these receptors initiate signaling 
by phosphorylation of tyrosine residues within the receptor.
• Type II growth factor receptors (Serine-threonine kinase receptors)
As with tyrosine kinase receptors the signalling event mediated by this class of 
receptors involves phosphorylation of serine and threonine residues within the 
receptor. Included in this group is the ras superfamily of signal transducer 
proteins. The active ras form activates a cascade of serine/threonine protein
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kinases controlling cell growth and differentiation, ras mutations are the 
commonest oncogenic abnormalities found in tumours, being present in ~20% 
of tumours.
• Type III growth factor receptors (G-protein-linked receptors or 
seven-transmembrane receptors)
These are the most common type of growth factor receptor. These receptors 
mediate their action by association with a family of adenyl cyclase and kinase 
regulating proteins via an intermediary -  the G protein (guanine nucleotide 
binding protein). All G-protein coupled receptors have 7 transmembrane 
spanning regions. Activation of the receptor leads to inactivation of these 
regulatory proteins and subsequent inactivation of intracellular signal 
pathways (140).
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3.2 Type I growth factor receptors
3.2.1 Characteristics of type 1 growth factor receptors
It has been known for over 30 years that EGFR is expressed in breast tissue where 
it plays a role in mitogenesis and differentiation. EGFR was the first type I growth 
factor receptor to be cloned (143). It showed considerable homology to the avian 
erythroblastosis virus transforming protein, v-erbB. Following the pioneering 
work of Cohen and colleagues, this receptor has served as a prototype for the 
understanding of tyrosine kinase signalling, receptor dimerization, and signal 
transduction cascades. The mutation or amplification of this gene can convert its 
cognate protein to a form that confers increased cancer risk on experimental 
animals and humans. The EGF family (i.e. ligands binding to the EGFR) now 
includes transforming growth factor alpha, amphiregulin, heparin-binding EGF,^- 
cellulin, the heregulins, cripto-1 and certain viral-encoded proteins.
To date, three other family members of this growth factor family have been 
identified: HER2 (144-146), c-erbB-3 (147; 148) and c-erbB-4 (149). These three 
receptors are also known as HER2, HER3 and HER4 (//uman Epidermal Growth 
Factor Eeceptor). (The last 2 members of this family will not be considered 
further in this work as they do not form any part of this study).
These receptor proteins have a common structure consisting of an extracellular 
domain, a transmembrane region, a short juxtamembrane sequence and a 
cytoplasmic domain. The extracellular domain is the ligand-binding area and 
contains two cysteine rich regions. The cytoplasmic domain consists of a tyrosine 
kinase domain and a carboxyl-terminal tail that contains the mapped
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autophosphorylation sites (150;151). A schematic diagram of this receptor family 
is shown in Figure 9.
The generally accepted mechanism of receptor activation is as follows: binding of 
ligand promotes receptor dimerization which increases the activity of the tyrosine 
kinase. This leads to specific tyrosine residues in the C-terminal tail becoming 
phosphorylated which then appear to serve as docking sites for molecules 
involved in signal transduction. Such molecules may be either substrates for the 
receptor tyrosine kinase or adaptor proteins involved in recruiting further proteins 
to the activated complex (152).
Study of this receptor family has resulted in critical insights into regulation of the 
normal mammary gland, in identification of one of the most commonly activated 
oncogenes in breast cancer (HER2), in recognition of critical mechanisms of 
breast tumour production, in identification of mechanisms of immune surveillance 
of breast cancer and in new ideas for drug therapy of the disease.
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3.2.2 Conventional methods for measuring type 1 growth factor receptors in 
breast cancer
Previous examinations of the relationship between type 1 growth factor receptors 
and breast cancer have primarily used two types of methodology: 
immunohistochemistry on tissue sections and ligand binding or ELISA based 
assays on tumour homogenates.
The ligand binding assay is the most widely applied method used to measure 
EGFR expression (153). This method requires a relatively large amount of fresh 
frozen tissue, is cumbersome to perform and cannot be applied to archival 
material. Other methods which have been used include enzyme immunoassay 
(154) which also requires frozen tissue, mRNA detection methods (155), 
autoradiography (156) and EGFR associated phosphotyrosine kinase activity 
(157). Initial studies of EGFR expression using immunohistochemistry (158;159) 
were significantly hampered by the need to use frozen tissue. This is because the 
majority of antibodies recognise an epitope on the internal domain of this 
transmembrane molecule which does not survive routine formalin fixation. 
Although ligand binding assay is generally accepted as the 'gold standard' in 
EGFR measurements, even here there is disagreement about the cut-off level used 
to define positivity. (160). Several studies using immunohistochemical (161-163) 
and ligand binding (164) methods have shown EGFR expression more frequently 
in non neoplastic than in malignant tissue. These assays are performed on 
membrane preparations derived from tumour biopsies which include, besides 
malignant cells, nontumour elements, including normal breast, in situ disease, 
connective tissue and lymphoid cells. As such the technique is inherently flawed
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since receptor measurement reflects the level of expression by the entire tumour 
mass rather than by the carcinoma cells alone. The inclusion of even small 
quantities of non-malignant tissues may cause a severe overestimation of the 
EGFR level. This is especially relevant with regards to this particular receptor 
protein as several studies have shown it to be preferentially expressed in stromal 
and myoepthelial cells and not in epithelial cells (165).
Newby et al (166) have recently developed an immunohistochemical assay which 
appears to work on paraffin embedded sections; using an IgG antibody produced 
by Biogenex, USA and which may have potential for use on archival material.
No definite ligand for the HER2 receptor has yet been identified and so ligand 
binding techniques are not currently applicable. Most studies of HER2 expression 
in breast cancer have used immunohistochemical analysis of formalin-fixed, 
paraffin-embedded tissues. Most antibodies used recognise an epitope on the 
internal domain of this transmembrane molecule which, unlike epidermal growth 
factor receptor, survives routine fixation and allows paraffin sections to be used. 
This type of assay suffers from a number of limitations and may not be 
sufficiently accurate to thoroughly assess the relationship between the levels of 
HER2 expression and the biology of breast cancer for the following reasons:
• First, routinely processed material may be fixed for times ranging from a 
few hours to several days, which is likely to result in variable antigenicity, and 
tissue in the centre of a large block will have a lesser degree of fixation 
compared to tissue on the periphery, which may explain the variation in 
staining commonly seen across an individual section.
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• Second, the many methods for amplifying the signal generated by binding 
of the primary antibody result in a range of sensitivities.
• Third, methods for scoring immunohistochemical sections are subjective, 
with a high degree of interobserver variability.
These factors are likely to lead to significant interstudy variation and may account 
for the wide range of values (9-39%) for the proportion of breast tumours reported 
to overexpress HER2 (167).
Studies of HER2 in breast cancer using Southern, Northern and Western blots use 
tissue homogenates and suffer from the same drawbacks as the ligand-binding 
assay for EGFR.
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3.3 Biology of EGFR
The EGFR is a 170 kDa transmembrane glycoprotein translated from mRNAs of 6 
and 10 kb encoded by a gene on chromosome 7q21. The protein comprises a 1186 
amino acid polypeptide chain (168) and, like the other members of the family, is 
composed of 3 domains: an extracellular ligand-binding domain, a transmembrane 
lipophilic region, and an intracellular protein tyrosine kinase domain. The EGFR 
signal transduction pathways have been correlated with various processes that 
contribute to the development of malignancies, such as effects on cell cycle 
progression, inhibition of apoptosis, angiogenesis, tumour cell motility, and 
metastases (169-172).
EGFR is expressed in many normal cells and organs. Hepatocytes, pancreatic 
ducts, oropharynx, salivary glands, uterus, prostate and the epididymis all show 
strong immunohistochemical staining, whilst the brain, spleen, lymph nodes and 
stomach are essentially negative.
3.3.1 EGFR in Normal Breast Tissue
There have been a limited number of studies investigating the expression of 
EGFR in normal breast tissue. However, it has been found in general that EGFR is 
expressed more frequently in non-malignant than malignant breast tissue 
(164; 173; 174). In addition some reports have shown that the level of EGFR 
expression is higher in normal tissue than malignant (164; 175). There seems to be 
a lack of the inverse relationship between EGFR and oestrogen receptor 
expression, which is found in malignant tissue, in normal breast tissue (164; 176). 
It is not known if the two receptors are co-expressed in the same cells, though 
Berthon et al (177) found that when human mammary epithelial cells are
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propagated from breast tissue obtained by mammoplasty, the cells are exclusively 
positive for EGFR and negative for oestrogen receptor.
Epidermal growth factor (i.e. the ligand for EGFR) is an important growth factor 
in the mammary gland of mice and is abundant in human breast milk. It is also 
essential for the growth of normal epithelial breast cells in culture (178). There is 
in vitro evidence of an interaction between EGFR and its ligands in normal breast 
cells (179). In breast cancer cells, it has been shown that TGF-a is an essential 
autocrine factor secreted under oestradiol control and that its level of expression, 
as well as that of EGFR mRNA, is under the control of EGF (180). Thus, EGFR 
and its ligands interact to regulate the growth of epithelial cells, at least in vitro, 
and can be influenced by oestradiol, a mitogen for breast cells. However, the 
relevance of these different pathways in vivo is unclear.
Immunohistochemical studies of EGFR in normal breast tissue are rare, and the 
few available studies give conflicting results (165;181-183). Damjanov et al (183) 
described positive staining of epithelial and myoepithelial cells coexisting with 
negative staining of stromal cells. Tsutsumi et al (181) described predominant 
staining in myoepithelial cells, occasional staining in fibroblasts and negative 
staining in epithelial cells. Gompel et al (165) report predominant staining in 
stromal and basal cells of large ducts.
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3.3.2 EGFR and DCIS
There is a distinct lack of studies investigating EGFR expression in DCIS, 
perhaps because of the added difficulty of having to use frozen tissue.
3.3.3 EGFR and Invasive Breast Cancer
In vitro, EGFR and its ligands have been implicated in malignant transformation 
via autocrine and paracrine growth factor pathways (184). In vivo, EGFR is 
expressed in a number of human tissues, both benign and malignant. Among 
cancers, EGFR is most strongly expressed in squamous cell carcinomas, but it is 
also found in a variety of other tumours. The incidence of expression in breast 
carcinomas (using ligand based studies) averages 49% with an interstudy range of 
16-91% (160). Similarly, immunohistochemical studies show that about 40% of 
breast cancers express EGFR with an interstudy variation of 14-65% (160). A 
number of studies have shown it to be an adverse prognostic factor in breast 
cancer (173; 185-193), though this is not confirmed in all such studies 
(155;160;193-195). These conflicting results are, at least in part, likely to be due 
to differences and the lack of standardisation between the assays used. In contrast, 
the literature is consistent in reporting an inverse relationship between EGFR and 
ER (160). EGFR positivity has also been shown to be an indicator of a poor 
chance of response to endocrine therapy (187;196;197).
Sainsbury et al (198) first described EGFR as a prognostic factor in human breast 
cancer in 1985 (using a ligand binding assay method). Since then there have been 
a large number of studies which have measured EGFR in breast cancers by a 
variety of methods and with differing definitions and proportions of positivity.
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3.4 Biology of HER2
The HER2 receptor gene is present on chromosome 17q21 and is transcribed into 
a 4.5 kb mRNA which is translated into a 185 kDa glycoprotein with tyrosine 
kinase activity (199). Structurally the HER2 receptor shares significant homology 
with, but is distinct from, the EGFR (146;200-202). Low levels of HER2 
expression are detectable immunohistochemically in a variety of epithelial cells 
throughout the gastrointestinal, respiratory and genitourinary tracts (203). 
Amplification of the HER2 protooncogene or overexpression of the receptor 
protein has been identified in gastrointestinal, pulmonary, and genitourinary 
tumours as well as in breast cancers (204-207). Laboratory studies suggest that 
overexpressed HER2 plays a direct role in the pathogenesis and aggressiveness of 
tumours through several lines of experimental evidence:
• transfection of HER2 into non-neoplastic cells effects malignant 
transformation (208;209)
• transgenic mice expressing HER2 develop mammary tumours (210)
• the presence of HER2 overexpression may be associated with the development 
of metastatic disease (210).
The mechanism by which overexpressed HER2 leads to a neoplastic phenotype is 
associated with at least 2 factors:
• its ability to induce resistance to tumour necrosis factor-a, which is a protein 
that has been shown to play an important role in tumour cell killing in vitro as 
well as in vivo via cytotoxicity mediated by macrophages and natural killer 
cells (209)
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• its activation of several different signalling pathways that lead to gene 
activation and, ultimately, cell proliferation (205)
The mechanism of activation of HER2 is thought to involve the formation of 
spontaneous homodimers or heterodimers with other members of the same family 
of growth factor receptors (211-214). As previously stated, no definite ligand has 
yet been identified for HER2. However, a family of ligand peptides named “neu 
differentiation factors” or “heregulins” have been identified that bind to the c- 
erbB-3 and c-erbB-4 receptors. This induces heterodimerisation with the HER2 
receptor, thereby inducing phosphorylation and activation of the HER2 receptor . 
It has also been shown that on binding of ligands such as EGF or TGFa to the 
EGFR, heterodimers between the EGFR and HER2 can also form (214).
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3.4.1 HER2 in Normal Breast Tissue
The precise physiological actions and regulation of HER2 in normal breast tissue 
are unknown. HER2 is expressed in many cell types including those outside the 
haematological system; expression has been found in neural tissue, bone, muscle, 
skin, heart, lungs and intestinal epithelium (144). Expression levels are higher in 
fetal tissues than in corresponding adult tissues (203), suggesting a role in cell 
differentiation. The activity of the HER2 receptor in tissues is affected by the 
variety of ligands and other HER receptors that are present. For example, EGFR 
and HER2 are often co-expressed and heregulins and EGF-like ligands are known 
to be able to activate HER2 via both autocrine and paracrine mechanisms 
(215;216). Studies have demonstrated that EGF-like ligands and neuregulins can 
inhibit or stimulate cell proliferation depending on the cell line tested (217;218). 
Neuregulins induce both growth and differentiation in a rodent cell model of 
mammary cell differentiation (219). In vivo treatment of mammary glands with 
EGF results in alveolar and ductal epithelial differentiation (220).
Studies of HER2 immunohistochemical staining in frozen tissue sections of 
normal human breast tissue have shown exclusive localisation to the epithelial 
compartment (165;179;203). Double labelling studies of EGFR and HER2 
immunohistochemical staining show that the proteins can coexist in mature 
epithelial cells in the normal breast, albeit with differential distribution: EGFR is 
preferentially present in the stroma and myoepithelial cells whereas HER2 is 
exclusively expressed in epithelial cells of lobules and ducts (165).
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3.4.2 HER2 and DCIS
At the molecular level, the stepwise enhancement of the histological grade of 
cancer cells within individual cancers is generally accompanied by the 
accumulation of alterations in oncogenes and tumour suppression genes. Gene 
alterations have been shown to accumulate in breast cancers with high grade 
atypia (221-224) and studies have shown that these alterations occur during the 
preinvasive stages (225-228). A much higher proportion of cases of pure DCIS 
express HER2 than do invasive carcinomas: between 45% and 60% of DCIS 
staining positively compared to only 20-25% of invasive carcinomas (30). The 
exact significance of this is unclear but there have been attempts to explain it (see 
section 3.6).
Many antibodies have been raised against HER2 and used in several studies to 
evaluate the relationship of HER2 to various histological features. A study by van 
de Vijver et al (using the 3B5 monoclonal antibody) was one of the first to show 
that nearly all DCIS with HER2 overexpression had a large cell comedo type 
histological appearance (30). In the same study, none of 16 cases of DCIS with 
small cell papillary or cribriform pattern stained positively for HER2. In a study 
of 74 cases of DCIS, Ramachandra et al (using the 2 IN antibody) (229) found a 
significant correlation between HER2 positivity and large cell size, periductal 
lymphoid infiltrate, marked nuclear pleomorphism, multinucleation and a high 
mitotic rate. Using the same antibody, Bartkova et al (230) found that all cases of 
large cell comedo type DCIS were positive for HER2 while no cases of small cell 
DCIS, usually with a cribriform or micropapillary pattern were positive. Lodato et 
al (231) found that in cases of DCIS with more than one type of histological
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pattern, positive staining was only present in the comedo areas. Studies by 
Bobrow et al (232) and Zafrani et al (233) have found an inverse relationship 
between the degree of differentiation in DCIS and the proportion of cases staining 
positive for HER2. Both studies also showed a direct relationship between the 
degree of necrosis and HER2 staining. The importance of nuclear grade in DCIS 
and the presence or absence of necrosis has been recognised (37). Nuclear grade, 
in particular, has been shown to correlate with subsequent development of 
invasive carcinoma (36;42;43). High levels of HER2 are found in comedo DCIS, 
and in general low or absent levels of expression are seen with other subtypes 
such as papillary and cribriform in situ tumours (234;235). The high levels of 
staining and high incidence of HER2 positivity in DCIS, together with the 
absence of expression in premalignant breast epithelial cells such as atypical 
ductal hyperplasia, indicate that HER2 expression may be an early event in the 
progression of tumorigenesis (236).
These studies show that HER2 positivity is associated with markers of more 
aggressive forms of DCIS. It follows that HER2 positivity may help identify more 
aggressive lesions which may be more likely to develop into invasive carcinoma.
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3.4.3 HER2 and Invasive Breast Cancer
Amongst the invasive tumours, ductal carcinoma is associated with HER2 
overexpression whereas lobular carcinoma is in general negative (235).
3.4.3.1 HER2 as a prognostic factor
A prognostic factor is one that provides information regarding patient outcome at 
the time of diagnosis. In 1987, Slamon and colleagues were the first to report a 
relationship between HER2 amplification and prognosis in breast cancer (221). In 
this study, 28% of the primary breast cancers studied showed a 2-20 fold gene 
amplification as assessed by Southern blot analysis. On multivariate analysis, 
HER2 amplification retained its independent prognostic significance when 
compared with size of tumour, hormone receptor status and number of lymph 
nodes involved (221;237). A subsequent study performed by the same group (238) 
confirmed the independent prognostic significance of HER2 amplification in 
predicting disease free survival and overall survival in a subgroup of node positive 
patients but not in a subgroup of node negative patients.
The methods used for assessing gene overexpression have included Southern blot 
analysis, slot blot testing, polymerase chain reaction, fluorescence in situ 
hybridisation and chromagenic in situ hybridisation. For assessing protein 
overexpression, Western blot analysis, immunohistochemistry and enzyme linked 
immunosorbent assays have been used (200). The majority of studies suggest gene 
amplification in approximately 20% (234) of breast tumours and the highest rate 
of protein overexpression recorded is 39% (239) (Range 9-39%, reviewed by 
Gullick (167)). Gene amplification is always accompanied by mRNA and protein 
overexpression (221), however overexpression can occur independently of
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amplification (240) and thus deregulated transcription may also be an important 
factor influencing HER2 expression. It appears likely that increased transcription 
precedes amplification in the natural history of breast cancer and that selection of 
cells expressing progressively higher levels of the receptor occurs.
Since these initial studies, at least 52 publications evaluating approximately 
16,975 patients have explored the prognostic significance of HER2 gene 
amplification and protein overexpression (reviewed by Kaptain et al (241), Ross 
and Fletcher (242)). Overall, 46 of the 52 studies (88%) have shown that HER2 
amplification or overexpression predicted a worse outcome in either univariate or 
multivariate analysis. Six of the 52 studies (12%) showed no correlation between 
HER2 status and outcome. Thirty-nine of the 46 studies showing a positive 
correlation between HER2 status and outcome included multivariate analysis. Of 
these 39, 33 showed that HER2 was an independent prognostic indicator while in 
6 of the studies, HER2 status was an independent prognostic indicator in 
univariate analysis only. The prognostic significance of HER2 status has been 
analysed in the context of subgroups of patients with positive and negative lymph 
nodes.
3.4.3.1a HER2 in lymph node positive breast cancer
The majority of studies that have looked at the prognostic significance of HER2 in 
patients with positive axillary lymph nodes have shown an adverse outcome 
associated with HER2 amplification or overexpression in univariate or 
multivariate analysis (221;238;243-257). In addition, many of these studies have 
shown that it maintains independent prognostic significance in determining 
shorter disease free survival and / or overall survival in multivariate analysis
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(221;238;245;247;249-257). Only a very few studies have not shown a 
statistically significant correlation between HER2 status and adverse outcome 
(208;258).
3.4.3.1b HER2 in lymph node negative breast cancer
The prognostic significance of HER2 in node negative breast cancer is less clear 
than in that of node positive disease. Many studies have shown that HER2 
amplification or protein overexpression is associated with an adverse outcome 
(245;250;251;256;257;259-263) or in certain subsets of patients with node 
negative disease (264-266). However, an equal number of studies have shown no 
significant difference in outcome associated with HER2 amplification or protein 
overexpression (208;238;243;244;247-249;252;253;255;267-269). In addition, 
only a few studies that have shown a prognostic importance for HER2 status in 
patients with negative lymph nodes have shown that it maintains an independent 
significance for disease free survival and/or overall survival in multivariate 
analysis (245;250;251;256;259;262). The reasons for these conflicting results 
include small patient numbers in many of the studies, patient selection, variations 
in treatment, length of follow up, statistical analysis, and in methodology used to 
assess HER2 status. Examination of studies that have involved more than 100 
patients with more than 3 years follow up (237) shows equally conflicting results. 
Thus, although it is generally accepted that patients with positive lymph nodes 
and HER2 amplification or overexpression have a worse prognosis, the prognostic 
significance of HER2 status in patients with negative lymph nodes is unresolved.
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3.43.1c HER2 and other prognostic factors in breast cancer
Controversial results have also plagued attempts to correlate HER2 amplification 
or overexpression with other prognostic factors in breast cancer. Many studies 
have shown an association between HER2 amplification or overexpression and 
the absence of oestrogen receptors or progesterone receptors (221;243- 
246;249;251;253;254;257;259;270-273), while others have not 
(208;260;262;269;274-278). Many studies have correlated HER2 amplification or 
overexpression with poor histologic or nuclear grade of the primary tumour 
(221;244-246;254;255;257;259;260;266;275;277;279;280), while others have not 
(249;258;259;262;265;269;272;274;276). Similarly, the association with positive 
lymph node status found in some studies (221;243;246;248;251;253;254;270;278) 
has not been confirmed by others (208;243;245;249;250;255;257;258;272;274- 
277). Most studies have not found an association with tumour size (221;248- 
251;253-255;257;259;260;262;265;270;271;276;277) although a few have found 
an association with tumours greater than 2cm in size (243;244;258;281). Other 
studies have associated HER2 amplification or overexpression with a higher 
tumour cell proliferation rate as shown by mitoses (255;272)147 or a higher S- 
phase fraction (244;259)(Reviewed by Kaptain et al (241)).
As is the case with EGFR, there is a tendency in some studies to view any 
expression as overexpression. Clearly this can be misleading as normal breast 
tissue has a degree of expression of both of these growth factors 
(162; 164; 173; 175;282). The correlation between HER2 expression and prognostic 
factors in some of these studies may therefore be irrelevant.
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3.4.3.2 HER2 as a predictive factor
A predictive factor is one that provides information regarding the likelihood of 
response to a given therapeutic modality. There has recently been great interest in 
the interactions between HER2 overexpression and various forms of systemic 
therapy in patients with breast cancer as this could potentially provide information 
that helps in determining the most suitable treatment for any given patient.
3.4.3.2a HER2 and anthracyclines
The most convincing evidence of such an interaction has been seen in patients 
with chemotherapeutic regimens containing anthracyclines. These studies have 
generally shown that HER2 overexpression is associated with increased 
sensitivity to anthracyclines (283-285). In vitro studies have shown that 
amplification or overexpression of HER2 in breast cancer cells is frequently 
correlated with coamplification/expression of topoisomerase Ila 
(211;283;286;287). Topoisomerase Ila is an enzyme involved in DNA replication 
that acts by generating and resealing double stranded DNA breaks (286;287). 
Topoisomerase Ila is a target for several anticancer drugs, including doxorubicin 
(211;283;286;287), which inactivate this enzyme, leading to the accumulation of 
double-stranded DNA breaks, which are lethal to the cell (286). Sensitivity to 
these chemotherapeutic agents is correlated with the level of expression of 
topoisomerase Ila (287). This may explain the sensitivity of HER2 amplified or 
overexpressing tumours to anthracycline containing chemotherapeutic regimens 
(211 ;287).
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3.4.3.2b HER2 and CMF regimens
Various studies have evaluated the effectiveness of chemotherapeutic regimes 
containing cyclophosphamide, methotrexate and fluorouracil (CMF) in patients 
with or without HER2 amplification or overexpression (288). Initial studies 
(245;264), published in 1992, looking at HER2 status in response to CMF 
treatment regimens suggested HER2 positive tumours showed a decreased 
response to CMF therapy. However, both these studies had small numbers of 
patients in the HER2 positive subgroups and small numbers of relapse events in 
these subgroups. They may, therefore, have been underpowered and a beneficial 
effect of treatment may have been missed (289). Several other studies have also 
shown a relative resistance of HER2 positive tumours to CMF treatment 
(207;211;245;254;264;289). However, a recent study (273) has found that both 
HER2 positive and negative tumours, as detected by immunohistochemistry, 
benefit from CMF treatment.
3.4.3.2c HER2 and taxanes
In a study performed at Memorial Sloan-Kettering Cancer Center (290), 
sensitivity to taxanes was studied in a group with metastatic breast cancer. The 
taxane used was Paclitaxel, which has been found to be active against many 
cancers which have been refractory to conventional chemotherapy. They found an 
overall response rate to Paclitaxel of 47%. Patients with HER2 positive tumours 
(37% overall) had a response rate of 65% while patients with HER2 negative 
tumours had a significantly lower response rate of 36%. Paclitaxel is thought to 
act via activation of the HER2 signal transduction pathway, which is thought to 
lead to drug-induced apoptosis (290). Nonetheless, these clinical trials are in
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conflict with experimental data that suggests that HER2 overexpression in 
transfected mammary cells leads to resistance to taxanes in vitro (291-293). 
3.4.3.2d HER2 and tamoxifen
The predictive effect of HER2 status has also been studied in relation to 
tamoxifen therapy. Expression of hormone receptors is associated with increased 
response (70-80%) to tamoxifen therapy among patients with advanced breast 
cancer, although up to 50% of patients with receptor positive tumours will not 
benefit from such treatment and approximately 10% of those with receptor 
negative tumours will respond (294). Most studies addressing this question 
conclude that patients with tumours with amplification or overexpression of 
HER2 do not respond or may even do worse with tamoxifen therapy 
(207;211;294-299). In contrast a study published in 1998 by Elledge et al (300) 
found no significant association between resistance to tamoxifen or worse 
outcome on treatment with tamoxifen in patients with metastatic tumours that 
were positive for both oestrogen receptors and HER2.
3.4.3.3 Summary
There is fairly consistent evidence that HER2 overexpression is predictive of 
sensitivity to anthracyclines. Although patients with HER2 overexpressing 
tumours may be less responsive to CMF treatment and to tamoxifen than those 
with tumours that do not show HER2 overexpression, current data are insufficient 
to deny patients treatment with either CMF or tamoxifen on the basis of the HER2 
status of the tumour.
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3.5 Targeting type 1 growth factor receptors in the treatment of breast 
cancer
Systemic treatments for breast cancer have improved significantly over the last 25 
years. New insights into cancer biology, refinements in biotechnology, and 
bioengineering of macromolecules may provide even greater reductions in breast 
and other cancer mortality through the use of “biologicals”. Biologicals are 
defined by the World Health Organisation as being molecules of complex 
structure resulting from genetic expression in living organisms. As molecules with 
mechanisms of antitumour actions that are different from those of existing 
therapeutics, they have potential to further improve clinical outcomes through 
combination with other modalities. New biological therapies have been evaluated 
clinically and confirmed to have curative and palliative potential, starting with the 
introduction of recombinant DNA-produced interferons into clinical trials about 
20 years ago. Part of the improved outcome with biologicals for cancer therapy 
has resulted from either augmentation of host inflammatory immune responses by 
manipulation of cytokines or through antigen specific therapies such as 
monoclonal antibodies. Monoclonal antibodies, targeted to the CD20 antigen on 
B-cell lymphomas or HER2 on breast carcinoma or other adenocarcinoma cells, 
represent the first antigen-specific biological therapies for cancer. The clinical 
results with the monoclonal antibody to HER2 have demonstrated that biological 
therapies for breast cancer hold significant promise. A phase II study reported by 
Baselga et al (301) of 45 women with HER2 overexpressing metastatic breast 
cancer, resistant to multiple previous therapies, showed that 11.6% and 37% of 
patients, respectively, developed objective response and disease stabilization
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when given monoclonal antibody rhuMAB HER2 [Herceptin, (trastuznmab)] 
directed against HER2. Herceptin has a favourable toxicity profile, and has 
achieved a significant overall response rate of 15% when given alone in metastatic 
breast cancer to patients whose tumours have progressed after chemotherapy 
(302).
The results of a randomised multinational controlled phase III clinical trial using 
Herceptin have now been reported (303). In this trial, the effect of Herceptin given 
in addition to first-line chemotherapy for metastatic disease was assessed in 469 
women whose tumours overexpressed HER2. Patients who had not received 
anthracycline-based adjuvant chemotherapy (n=281) were treated with 
doxorubicin and cyclophosphamide and randomly allocated Herceptin or no 
additional treatment. Patients who had received anthracycline-based regimens as 
adjuvant therapy (n=188) received paclitaxel with or without Herceptin. Addition 
of antibody to chemotherapy increased the response rate and the time to 
progression, and was associated with a survival advantage of 5 months, although 
65% of patients who were not allocated Herceptin initially received it on relapse. 
These results suggest that use of anti-HER2 antibody therapy has potential as a 
new method of breast cancer treatment, whether given alone or in combination 
with other treatment methods. Additional approaches to anti-HER2 therapy under 
investigation include the use of antisense gene therapy probes and anti-HER2 
vaccination.
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3.6 Expression of HER2 in DCIS compared to that in invasive carcinoma
An interesting issue with regards to HER2 expression in both DCIS and invasive 
carcinoma is the reason why more DCIS lesions express HER2 (45-60%) than 
invasive lesions (20-25%). In a paper published in 1992, Barnes et al (159) 
attempt to explain this. They suggest that, with regards to HER2 expression in 
invasive carcinomas there are 3 groups of tumour:
• those composed of cells with small nuclei, which have arisen from small cell 
DCIS. These have a low rate of proliferation and of HER2 overexpression
• those composed of large cells which have arisen from large cell DCIS. These 
have a high rate of proliferation and of HER2 overexpression
• those composed of cells with variable nuclear sizes, but including some with 
large nuclei, over half of which have a high rate of proliferation but none of 
which overexpress HER2
They hypothesise that this last group of tumours only have a transient in situ stage 
and quickly become invasive, explaining the lower rate of overall HER2 positivity 
seen in studies of invasive carcinomas when compared to pure in situ lesions.
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SECTION 4 AIMS OF TfflS STUDY
The breast cancer research group at the Department of Surgery, Glasgow Royal 
Infirmary, has previously reported the development of radio-immunohistochemistry 
for quantifying epidermal growth factor receptor (EGFR) and HER2 in frozen tissue 
sections and applied this method to breast tumours (1). This 
radioimmunohistochemistry method is highly sensitive and allows the quantitation of 
receptor levels throughout the range of expression in breast carcinomas. The 
quantitative, objective data produced allow a more thorough evaluation of the 
relationship between receptor expression and tumour biology. The aims of this study 
are to answer the following questions using this quantitative assay:
1. Are the levels o f expression o f these type 1 growth factor receptors seen in 
invasive lesions the same as in situ breast cancer, and might these be a factor in 
determining progression to invasive disease?
If EGFR downregulation or HER2 overexpression are required for progression to 
invasion we might expect to see more lesions with normal levels of expression in 
pure DCIS, and an invasive or intermediate pattern in DCIS adjacent to invasive 
areas. In this way, the quantitative information available from radio­
immunohistochemistry may allow us to predict the biological role of EGFR and 
HER2 in breast carcinogenesis and progression.
2. What is the relationship between the expression o f these type 1 growth factor 
receptors and morphological features and histologic subtype o f DCIS?
Studies of DCIS correlating HER2 expression to morphological features such as 
cell size and nuclear differentiation have found expression exclusively within
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DCIS composed of large cells containing poorly differentiated nuclei. Studies 
correlating histologic subtype of DCIS have found a significantly higher 
prevalence of HER2 protein expression in the comedo subtype than the 
cribriform-micropapillary subtype. Very few studies have looked at EGFR 
expression in DCIS.
The quantitative information available from radio-immunohistochemistry will 
allow us to characterise further the relationship between these type 1 growth 
factor receptors and morphological features known to be associated with more 
aggressive forms of DCIS.
3. What is the relationship between HER2 expression, particularly sub- 
amplification levels, and pathological variables and outcome as measured in a 
large series o f primary breast cancers?
As previously stated the breast cancer research group at Glasgow Royal 
Infirmary has applied this radio-immunohistochemical method to a series of 
primary breast cancers (1) (n = 118 for EGFR, n = 81 for HER2, n = 75 for both 
receptor types). In this small number of tumours studied, there is a suggestion 
that HER2 correlates better with pathological predictors of outcome when cut­
offs below the very high levels seen with amplification are used. As part of this 
work, using tumours from the frozen tumour bank at Glasgow Royal Infirmary, 
this series has now been extended to 193 tumours for EGFR and 177 for HER2. 
The question as to the biological importance of HER2 expression at these lower 
levels is explored using patient outcome as the indicator of biological activity, 
studied against the exact level of expression as measured by radio- 
immunohistochemistry.
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SECTION 5 MATERIALS AND METHODS
All specimens in this study were frozen tissue samples. All clinical follow-up was 
carried out in a specialist breast cancer unit (either WIG or GRI). All specimens 
were examined by a dedicated breast pathologist (EAM or JJG). A diagram of the 
methodology is shown in Figure 10 below.
* f
Follow up (invasive tumours)
Details of follow up entered 
prospectively into a database
Invasive lesions:
Tumour and patient details 
recorded in a database
Frozen tissue bank
Samples stored in a frozen tissue 
bank at -20°C in airtight 
packaging until use
Radioimmunohistochemistry
Expression of EGFR and HER2 
in the samples quantified using 
radioimmunohistochemistry
Tumours:
Invasive disease alone
Pure DCIS
DCIS associated with
invasive disease DCIS lesions:
Nuclear grade and presence or 
absence of necrosis recorded by 
EAM or JGG to establish VNCS 
grading
Figure 10. A schematic diagram o f the methodology used.
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5.1 Tumour populations
Three tumour populations were studied and 1 population of normal breast tissue.
5.1.1 Normal breast.
This study has used specimens of histologically normal breast which were 
obtained from 9 reduction mammoplasty procedures, in a manner similar to that 
for tumour biopsies. Blocks macroscopically containing breast parenchyma, 
subsequently confirmed on H&E sections, were dissected from the surgical 
specimen. The median age of the patients from whom these specimens were 
obtained was 35.5 years, with a range from 17-49 years. Counts were carried out 
over terminal ducts and lobules, and not over major ducts. These specimens are 
the same ones which have formed the basis of “normal” receptor expression in 
previous work by this group (1;2;304).
5.1.2 Pure ductal carcinoma in situ (DCIS) with no evidence of invasion.
A frozen tissue bank of pure in-situ carcinoma was collected prospectively. Cases 
likely to contain DCIS were highlighted prior to surgery. The majority of these 
were screen detected lesions. A single dedicated breast pathologist (EAM) 
processed the tissue in the usual manner and if it contained only DCIS, cryostat 
sections (5 pm) were thawed onto silanized slides and stored at -20°C in airtight 
packaging until use. The diagnosis of pure DCIS was later confirmed by checking 
the final pathology report. Forty samples of pure DCIS were obtained in this way. 
EGFR receptor levels were measured in 37 cases and HER2 receptor levels were 
measured in 36 cases. Both receptor types were quantified in 33 tumours. There 
were 7 cases in which receptor measurement was only possible for one or other 
receptor as the sections obtained for these research purposes either did not contain
tumour or the fixation process had altered the histology such that areas of tumour 
could not be reliably identified.
5.1.3 Ductal carcinoma in situ (DCIS) adjacent to invasive disease.
The same pathologist examined sections of invasive tumours to identify those 
tumours which also contained areas of in situ disease. The expression of EGFR 
and HER2 receptors within these areas of in-situ carcinoma were quantified. 
Levels for EGFR were measured in 50 tumours and HER2 receptors in 47. Both 
receptor types were quantified in 40 tumours. Once again, there were 10 cases in 
which receptor measurement was only possible for one or other receptor as the 
sections obtained either did not contain tumour or the fixation process had altered 
the histology such that areas of tumour could not be reliably identified.
5.1.4 Invasive tumours.
Unilateral, primary, operable breast cancer biopsies taken during lumpectomy or 
mastectomy procedures in Glasgow Royal Infirmary between 1984 and 1994 
formed the study material for the project. Biopsies were frozen and stored in 
liquid nitrogen. One hundred and ninety-three specimens were stained for EGFR 
and 177 for HER2. (The breast cancer research group at Glasgow Royal Infirmary 
have previously reported on the application of radioimmunohistochemistry to 
primary breast tumours. This work has expanded the number of tumours and 
examined long term follow up of these patients with regard to HER2). 
Pathological data including macroscopic tumour size and axillary lymph node 
status were recorded by the pathologist reporting on that specimen. Tumours 
were graded by a dedicated pathologist using Elston's modification of the Bloom 
and Richardson system (49). Slides of the sections were reviewed by a dedicated
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breast pathologist (EAM) to ensure they did not contain DCIS. Follow-up and 
survival information was obtained from unit records and confirmed with data from 
the cancer deaths registry of the West of Scotland Cancer Surveillance Unit, from 
whose records cause of death was taken. Median follow up for surviving patients 
at the time of analysis was 69 months (5.8 years).
This series of tumours do not represent consecutive tumours. Our results could 
therefore be criticised as it could be claimed these tumours were selected. The 
frozen tissue bank of pure DCIS was collected prospectively. All patients who 
were suitable i.e. had only DCIS and no invasive disease and had sufficient tissue 
available so as not to affect the histological examination of the case were used. 
Cases of DCIS in association with invasive disease were selected only for those 
that were shown to contain DCIS as well as invasive disease and for no other 
features.
The invasive tumours were those that were contained in the frozen tissue bank at 
Glasgow Royal Infirmary. The characteristics of the examined group were 
compared with those of other unilateral, primary operable tumours treated in the 
same unit during the time period that the frozen tissue bank was established. This 
data is shown in Table 21. The characteristics of the examined group and the 
unselected group are clearly comparable.
It should be mentioned that these 3 tumour populations involve different patients. 
Ideally, a population of patients who had progressed from DCIS to develop 
invasive disease would have been best to investigate whether a marker is a true 
test for disease progression. From what we know of the natural history of the
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disease, this is a process that can take many years. This population of tumours 
would have been very small, making it very difficult to draw any firm conclusions 
from the data.
5.2 Statistical analysis for HER2 in invasive tumours
Survival analysis was performed for HER2 expression in invasive tumours. This 
was performed for disease-specific survival, patients being censored at last 
follow-up or at the date of death from causes other than breast cancer.
Two types of analyses were performed.
a) Univariate and multivariate analyses using Kaplan-Meier estimates
The distribution of HER2 expression in invasive disease appears to be 
bimodal, with a nadir at about 15 times normal expression levels which is a 
level we have previously shown is due to gene amplification (2). This appears 
to give a natural division of HER2 expression into 3 groups:
Group A where expression is less than that of normal breast tissue.
Group B where expression is between normal and 15 times normal expression. 
Group C where expression is greater than 15 times normal expression. 
Univariate analysis comparing disease free survival in these 3 groups was 
carried out.
Multivariate analysis was carried out comparing disease free survival in these 
3 groups against known pathological variables and the Nottingham Prognostic 
Index.
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Univariate and multivariate analysis alone was felt to be inadequate as it ignores 
the quantitative continuous nature of the data, and gives arbitrary user defined 
categories. (Which is essentially what conventional immunohistochemistry does, 
except the categories are methodologically defined),
b) Cox’s proportional hazards model
Cox Proportional Hazard regression models are fitted to the data using the 
logarithm of HER2 as the quantitative diagnostic variable of interest. Linear, 
quadratic and cubic terms in log(HER2+l) are fitted. The fits are made both 
ignoring, and adjusting for, the status of standard pathological indicators 
(number of nodes, size and grade of tumours). The models are fitted both for 
the total sample, and within the two groups defined by Oestrogen receptor 
status.
The gain from adding terms to the model is examined using standard 
likelihood ratio tests. Where appropriate, stepwise fitting is employed using 
the forward likelihood ratio as the basis for selection of variables. 
Acceptability of the Proportional hazards component of the model is checked 
by visual examination of derived graphs.
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5.3 Radio-immunohistochemistry.
For EGFR and HER2 quantification the radio-immunohistochemical method used 
was that which has been previously described and validated by this group (1;305). 
A diagram of the radioimmunohistochemical method used is shown in Figure 11.
Iodinated Antibody— ►
Iodinated Antibody 
with excess unlabelled * 
antibody 
Grains per unit area 
per hour of exposure
Image Analysis +
(KS400 Kontron)
Figure 11. Schematic diagram o f the radioimmunohistochemical method.
Briefly, this method involves incubation of frozen tissue sections with 
radioiodinated anti receptor monoclonal antibody to label the receptors. The slides 
are then coated with autoradiographic emulsion and exposed and developed. This 
results in silver grains directly over the section. The density o f grains developed 
directly over the tumour cells is counted with an image analysis system. The grain 
density is converted to receptor density by comparison with a standard curve for 
each run, created by including sections of pellets of a panel of cultured cells of 
known receptor expression.
Slides dipped in 
autoradiographic emulsion
i
— Expose & Develop
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The following protocols were developed for each stage of this technique:
5.3.1 Iodogen catalysed antibody iodination
The EGFR1 monoclonal antibody is of the IgG2 class and recognises an epitope 
on the external domain of the EGF receptor (306). The ICR12 rat IgG2a 
monoclonal antibody was raised to the external domain of the HER2 receptor of 
BT474 cells (307) (a gift from C. Dean, Institute of Cancer Research, Sutton, 
London). Both antibodies are iodinated by the Iodogen method to a specific 
activity of 0.5MBq/pg. This method is detailed in Harrow and Lane, Antibodies: 
A laboratory manual, 1988 (308).
5.3.2 Antibody application
i. Cryostat sections (5pm) are thawed onto silane coated slides and stored at 
-20°C in airtight packaging until use.
ii. When ready for use the slides are warmed to room temperature before the 
airtight packaging is removed to prevent the formation of condensation.
iii. To prevent drops of solution running off the tissue sections, the sections 
are ringed with a Dako pen (Dakopatts Ltd.).
iv. The sections are pre-fixed in 100 % acetone for 5 minutes.
v. Sections are then put through 2 washes of phosphate buffered saline (PBS 
= lOmM sodium phosphate and 140mM sodium chloride, pH 7.4)
vi. Incubate sections with lOOpl of blocking solution for 10 minutes to 
minimise non-specific binding. For test slides this blocking solution is 
50% normal rabbit serum in PBS. For the control sections this blocking 
solution is 50% normal rabbit serum with unlabelled antibody.
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vii. Add IOjjI of the radiolabelled antibody. The specific activity of the 
iodinated antibody was adjusted with unlabelled antibody so that 50ng 
(4KBq) Ii25EGFR1 or (50ng lKBq) I125ICR12 were added to each 
section. Duplicate test sections and a single control section (which is 
incubated with a 100-fold excess of unlabelled antibody) were processed 
for each specimen.
viii. Incubate sections for 3 hours in humidified chambers at 22°C.
ix. The sections are then washed through three 10-minute changes of PBS 
and fixed for 10 minutes in 2% formaldehyde.
x. Finally, the sections are washed through 3 changes of distilled water 
before being air dried.
5.3.3 Autoradiography
5.3.3a Determining exposure time.
i. One test slide from each case and cell line used is secured into an X-ray 
cassette and its position noted.
ii. In a dark room using a Wratten red filtered safe light, the slides are 
overlaid with X-ray film (Dupont Cronex) and exposed for approximately 
72 hours.
iii. This film is then developed and is used as a necessary guide to the 
optimum length of exposure for the final stage of the preparation, where 
the slides are dipped in autoradiographic emulsion.
iv. Separate the slides in racks according to the length of exposure. Racks of 
slides requiring the same exposure are then stored together in containers.
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5.3.3b Dipping in autoradiographic emulsion.
This part of the procedure must be carried out in a dark room using a Wratten red 
filtered safe light. It is essential that neither the emulsion nor the dipped slides are 
exposed to light at any time. All materials must therefore be brought into the dark 
room before starting the dipping process. The emulsion used is Kodak NTB-2 
diluted 1:1 with distilled water. This is stored in the dark at 4°C.
i. The emulsion is placed in a water bath at 42°C and allowed to liquefy for 
1 hour.
ii. Dip several plain slides to ensure that the emulsion is smooth, even and 
bubble free.
iii. Dip slides in the emulsion and drain excess emulsion from the bottom 
edge of the slide. Stand slides upright and allow to dry for approximately 
30 minutes.
iv. When slides are dry, place them into their appropriate racks, with slides 
requiring the same exposure times in each rack.
v. Place racks in a container with silica gel as a dehumidifier.
vi. Seal the container, place inside a black bin liner and store at 4°C.
vii. The slides are then exposed for the appropriate time: the highly 
expressing tumours and cell lines being exposed for 4 hours, the 
intermediate tissues for 24 and 48 hours and the weakly expressing 
specimens for 4 to 7 days. The correct exposure results in an optimum 
density of silver grains for counting. Overexposed sections where large 
numbers of grains fuse together were not used.
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5.3.3c Development of autoradiographs
Once again, this part of the procedure must be carried out in a dark room using a 
Wratten red filtered safe light. The slides should be allowed to reach room 
temperature before the container is opened.
i. Remove the slides from the container in the dark room, 
ii. The emulsion is developed with Kodak D 19 developer solution (1:1 in
distilled water). The developer solution is kept at 10°C by placing it on ice. Place 
the slides in the developer solution for 4 minutes.
iii. Rinse the slides in distilled water for 1 minute at room temperature.
iv. Place the slides in Kodak Unifix for 5 minutes at room temperature. After 
this stage the slides may be exposed to light.
v. The slides are then washed for 20 minutes through 4 changes of distilled 
water and then tap water.
5.3.3d Safranin counterstaining
At this stage the slides contain sections of tissue with silver grains on them. In 
order to accurately count the grains over the areas of interest, the sections are then 
counterstained lightly with Safranin O to allow the histology to be viewed.
i. From tap water, place the slides in Scots Tap Water Solution for 0.5-1 
minute.
ii. Rinse the slides in tap water.
iii. Place the slides in Safranin O solution for 1-2 minutes.
iv. Rinse the slides in tap water.
Steps i -  iv can be repeated at this stage if the staining is not deep enough.
v. The slides are then dehydrated and mounted through standard solutions.
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Figures 12-14 show examples of developed sections.
Lumen of 
duct
Figure 12.
■Stroma
0
Duct
containing
DCIS
Figure 13.
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Myoepithelial
cells
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Figure 14.
Figures 12, 13 and 14. Developed sections at X40 magnification. The number o f  
grains per unit area is then calculated as discussed below.
5.4 Image Analysis
In the previously reported study applying this method to invasive breast cancers a 
Joyce-Loebl MiniMagiScan image analysis system was used (2). In this study, 
expanding the number of invasive cancers and applying the method to DCIS, a 
Kontron KS-400 system was used. This was attached to an Olympus OM-2 
microscope for quantification of silver grain density. The operator defines areas of 
tumour and the system counts the silver grains per unit area. Counts are made over 
an average of 10 full or partial fields, with the histology being confirmed by the 
Safranin O counterstain in conjunction with serial H&E sections. Results were
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expressed as grains per unit area per hour of exposure after subtraction of the 
counts for the control slides.
Figures 15-17 show how the image analysis program quantifies the silver 
grains directly over the area of interest.
.  •* '  j s ; ^
: -**
Figure 15. A developed section at X40 magnification showing the terminal 
ductolobular unit containing DCIS.
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Figure 16. The operator then draws around the area containing DCIS, 
excluding stroma and the spaces within the duct.
Figure 17. Image analysis software then counts the number o f silver grains 
per unit area.
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5.5 Data Interpretation
Standardisation of results for each set of test sections is achieved by the 
concomitant running of sections of normal breast and sections of cell pellets. The 
latter are formed from cell lines with known receptor densities of EGFR and 
HER2. Pellets are formed by scraping sub confluent cell colonies, which are then 
centrifuged prior to snap freezing in liquid Nitrogen.
5.5.1 EGFR
For the EGFR assay the A431 cell line is used as a point standard. EGFR levels in 
the normal specimens was expressed as a percentage of the receptor density of the 
A431 cell line (which are known to have 2 X 106 EGFR/cell) (304;305).
Table 9 below shows the grain counts per unit area for the A431 cell line over the 
16 radioimmunohistochemistry runs that formed the basis of this work. This
clearly shows that the values did not vary greatly during the various passages.
Date of 
radioimmunohisto 
chemistry run
A431
GRAINS
Date of 
radioimmunohisto 
chemistry run
A431
GRAINS
06/04/1993 166.0 15/04/1994 160.0
13/04/1993 144.1 18/04/1994 190.0
04/05/1993 140.0 29/04/1994 148.1
06/05/1993 135.3 05/06/1995 121.3
11/05/1993 121.0 06/06/1995 131.6
08/06/1993 206.0 07/06/1995 160.6
10/06/1993 212.2 08/06/1995 152.1
14/04/1994 170.0 17/12/1997 147.1
Table 9. Grain counts per unit area for the A431 cell line for the 16 
radioimmunohistochemistry runs.
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5.5.2 HER2
HER2 expression spans a greater range and thus a number of lines are chosen to 
provide a similar range of standardisation points. In ascending order, these are the 
ZR75, MDA-MB-453, MDA-MB-361, BT474 and SKBR3 lines. Using the 
ICR12 antibody as a radiolabelled ligand, Scatchard analysis of receptor number 
on sections of cell pellets was performed using the LIGAND program. Ratios of 
receptor number by this method over grain counts per unit area by radio­
immunohistochemistry produce a linear scale. Few tumours fall outwith this scale. 
By incorporating this scale in each tumour batch, and with the receptor number in 
each cell line known from the Scatchard analysis, it is possible to define the 
number of receptors in terms of silver grains per unit area per hour of emulsion 
exposure. A conversion factor for receptor number per unit area is calculated by 
averaging the ratios for cell pellets. This, when applied to grain counts for the 
tumour biopsies in the same batch, allows calculation of receptor numbers.
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Cell line
Grain counts per unit 
area 
(RIHC)
Receptors by 
Scatchard analysis 
(mm2xl06)
Ratio
ZR75 0.49 10.9 22.20
MDA-MB-453 1.25 49.3 39.44
MDA-MB-361 3.94 131 33.20
BT474 11.49 581 50.60
SKBR3 21.05 687 32.60
Table 10. The grain counts per unit area for each o f the cell lines used and the 
corresponding receptors by Scatchard analysis. RIHC = 
radioimmunohistochemistry.
Above SKBR3 levels of HER2 expression, the scale loses linearity and receptor 
expression is underestimated. This applies to a few HER2 amplified tumours in 
this series but is unlikely to significantly influence the statistical analyses (Rank 
correlations will still apply). In all cases the quantity of receptor protein in the 
areas measured by image analysis is then compared with expression in normal 
breast tissue.
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5.6 Patient follow up
The patient population comprised both screen detected patients and symptomatic 
patients. Symptomatic patients were initially seen at a one-stop breast clinic where 
the diagnosis was made. All pathology and management decisions were reviewed 
at a multidisciplinary meeting attended by surgeons, oncologists and the breast 
pathologist (EAM).
After surgery patients were followed up at 3 monthly intervals for the first 2 years 
then 6 monthly for the next 3 years and annually thereafter. If breast-conserving 
surgery had been performed, mammograms were performed on the affected breast 
annually and the contralateral breast every 2 years. If treatment was by 
mastectomy a mammogram was performed on the contralateral breast every 2 
years.
After each clinic visit, details of follow up were entered into a database 
prospectively. The database management conformed to the data protection act.
5.7 Ethics
The study received ethical approval from the local ethics committee. In the late 
1980’s and early 1990’s it was not deemed necessary to obtain individual consent 
to keep discarded tissue following surgery. In the latter part of collection, generic 
consent was obtained to use this tissue for research purposes.
99
SECTION 6 RESULTS
6.1 Tumour characteristics
6.1.1 Pure DCIS
Forty samples o f pure DCIS were obtained as described in the Materials and 
Methods section. These were classified according to the Van Nuys DCIS 
Classification system as shown below in Figure 18 and Table 11.
Van Nuys DCIS Classification 
applied to Pure DCIS
1 2 3
Van Nuys DCIS Classification (Group 1-3) n = 40
Figure 18. Pure DCIS cases stratified according to the Van Nuys DCIS 
Classification system vs. Frequency, n = 40
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VNCS*
Group N %
1 7 17.5
2 21 52.5
3 12 30.0
Total 40 100.0%
Table 11. Pure DCIS according to Van Nuys DCIS Classification system groups 
1-3. *VNCS = Van Nuys DCIS Classification system.
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6.1.2 DCIS associated with invasive disease
Fifty cases of DCIS in association with invasive disease were obtained and 
classified according to the Van Nuys DCIS Classification system as shown below 
in Figure 19 and Table 12.
Van Nuys DCIS Classification 
applied to DCIS with Invasive Disease
1 2 3
Van Nuys DCIS Classification (Group 1-3)
Figure 19. Cases o f  DCIS associated with invasive disease stratified according to 
the Van Nuys DCIS Classification system vs. Frequency, n = 50
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VNCS*
Group N %
1 15 30.0
2 23 46.0
3 12 24.0
Total 50 100%
Table 12. DCIS associated with invasive disease according to Van Nuys DCIS 
Classification system groups 1-3. *VNCS = Van Nuys DCIS Classification system.
103
6.2 Results for EGFR
6.2.1 EGFR expression in normal breast tissue.
EGFR levels in the normal specimens are expressed as a percentage of the 
receptor density of a cell line standard, A431. A431 cells are known to have 2 X 
106 EGFR/cell (305;309). As described in the Materials and methods section, 
standardisation of results for each set of test sections is achieved by the 
concomitant running of sections of normal breast and sections of cell pellets. The 
latter are formed from cell lines with known receptor densities of EGFR and 
HER2. As shown in Table 13, normal levels of EGFR expression ranged from 5.2 
to 10%, with a mean of 7.6% of A431 levels of expression.
Number Range Minimum Maximum Mean
9 4.79 5.21 10.0 7.61
Table 13. EGFR expression in normal breast tissue expressed as a percentage o f  
A431 levels o f expression.
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In the analyses below, the level of expression of EGFR is expressed relative to the 
mean level of expression in these normal samples. Levels of EGFR expression are 
expressed on a log scale as they vary by a factor of several thousand. The 
reference line on the graphs is at the zero point and represents the level of 
expression in normal breast tissue.
6.2.2 EGFR expression in pure DCIS.
The frequency distribution of EGFR in pure DCIS is shown in Figure 20. All 
tumours show lower levels of expression than control breast reduction specimens.
EGFR expression in pure DCIS
10 T- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
LOG(EGFR X Normal) n = 37
Figure 20. Log io(EGFR X  Normal) vs. Frequency for pure DCIS.
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6.2.3 EGFR expression in pure DCIS as classified by the Van Nuys DCIS 
Classification system.
Levels of EGFR expression in pure DCIS groups 1, 2 and 3 of the Van Nuys 
DCIS Classification system were analysed using the Kruskal-Wallis test. There 
was no difference in EGFR expression between the 3 groups (p = 0.585). The 
descriptive statistics for expression of EGFR in these groups are shown in Table 
14.
VNCS*
Group
N Median
Interquartile
range
1 7 0.031 0-0.062
2 20 0.033 0-0.068
3 10 0.043 0-0 .17
Total 37
Table 14. Descriptive statistics for EGFR expression in pure DCIS according to 
Van Nuys DCIS Classification system groups 1-3. *VNCS = Van Nuys DCIS 
Classification system.
This implies that the level of EGFR expression is the same in each pure DCIS 
group as classified by the Van Nuys DCIS Classification system.
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6.2.4 EGFR expression in DCIS associated with invasive disease
6.2.4.1 EGFR expression in DCIS associated with invasive disease -  the DCIS
component
The frequency distribution of EGFR in the DCIS component o f DCIS associated 
with invasive disease is shown in Figure 21. All but 1 tumours show lower than 
control levels o f expression.
EGFR expression in DCIS with invasive disease 
- the DCIS component
12 -I 
10 - 
8->% o c  
<D3 6-cr 
<D
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4-
2- 
0.
-3.25 -2.50 -1.75 -1.00 -.25 .50
LOG(EGFR X Normal) n = 50
Figure 21. Logio(EGFR X  Normal) vs. Frequency for the DCIS component o f  
DCIS associated with invasive disease.
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6.2.4.2 EGFR expression in DCIS associated with invasive disease -  the
invasive component
The expression of EGFR of the invasive component for these same tumours is 
shown in Figure 22. All but 1 tumours downregulate EGFR in relation to normal 
breast. The tumour which had very high expression of EGFR in the DCIS 
component also had very high expression in the invasive component.
EGFR expression in DCIS with invasive disease 
- the invasive component
-3.25 -2.50 -1.75 -1.00 -.25 .50
LOG(EGFR X Normal) n = 50
Figure 22. Logio(EGFR X  Normal) vs. Frequency for the invasive component o f  
DCIS associated with invasive disease.
The expression of EGFR in the DCIS and invasive components of each tumour is 
similar. Indeed, when analysed using the Wilcoxon Signed Rank test, there is no 
significant difference in the expression of EGFR (p = 0.39) in each component of 
the tumours. This is shown in figure 23 below.
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oEGFR expression in the DCIS and invasive 
components of DCIS associated with invasive
disease
a
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Figure 23. EGFR expression in the DCIS and invasive components o f each 
tumour.
Although overall there appears to be no statistically significant difference between 
these 2 components of the tumours, some interesting findings can be found 
comparing the level of EGFR expression in the in situ versus the invasive 
components of the tumours of individual patients. In the graph above there are 
clearly some individuals whose expression of EGFR varies considerably in the in 
situ and invasive components. This is shown graphically in figure 24 below.
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Difference in EGFR receptors in DCIS 
compared to Invasive components
10
8
0
2
0
•2
EGFR X Normal
Figure 24. The size o f the difference in EGFR expression for those tumours with 
both DCIS and invasive components.
The 6 tumours with the largest change in expression from moving to in situ to 
invasive disease are presented in Table 15 below. The Nottingham Prognostic 
Index for the invasive components o f these tumours are also listed. Unfortunately 
only 3 of these 6 scores were available as one tumour was diffuse and the size of 
the other 2 tumours was not recorded.
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Patient ID
EGFR 
receptors in 
DCIS
EGFR receptors in 
invasive 
component
Difference NPI
DCIV37 2.77 10.98 8.21 N/A
DCIV24 0.02 0.51 0.49 N/A
DCIV27 0.00 0.46 0.45 5.4
DCIV4 0.06 0.41 0.35 5.5
DCIV47 0.03 0.24 0.20 4.6
DCIV26 0.45 0.19 -0.26 N/A
Table 15. The 6 tumours with the greatest change in EGFR expression between 
the in situ and invasive components. A positive value implies an increase in EGFR 
expression and a negative value a decrease. NPI = Nottingham Prognostic Index. 
N/A = Not available.
The NPI for 37 of the 50 invasive tumours was available, with a median of 4.40 
(interquartile range = 2.02). As only 3 of the 6 tumours with the largest change in 
EGFR expression had an NPI available the median here is 5.4. Using the Mann- 
Whitney U test there was no statistically significant difference in the NPI between 
those tumours that had the largest difference in EGFR expression in the in situ 
compared to the invasive components of the tumour and the other invasive 
tumours that had associated DCIS (p=0.13). There does however appear to be a 
trend towards significance and certainly those tumours that had a large change in
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EGFR expression appeared to do badly.
Patient DCIV37 with the largest such increase in EGFR expression between the in 
situ and invasive components in this series had a very aggressive tumour with 6 
out of 6 lymph nodes tested being positive. The tumour was multifocal and there 
was widespread lymphatic permeation and soft tissue metastases in the axilla. 
Patient DCIV24 had a poorly differentiated tumour with a positive lymph node 
and developed liver metastases.
Patient DCIV27 had a lobular carcinoma with an NPI of 5.4 and 19 out of 19 
positive lymph nodes.
Patient DCIV4 also had a ductal carcinoma with an NPI of 5.5 and 4 out of 7 
lymph nodes involved with tumour.
Patient DCIV47 also had a node positive breast cancer which recurred in the chest 
wall post mastectomy and later recurred in the axilla.
Patient DCIV26 had the largest fall in EGFR expression between the DCIS and 
invasive components of the tumour. This was also an aggressive lesion with 5 out 
of 9 lymph nodes positive and went on to develop pulmonary metastases.
While this data is not scientific and the change in EGFR expression between the 
DCIS and invasive components of the tumours does not reach statistical 
significance, it is interesting to note these individual cases of clearly aggressive 
tumours where the change in expression from DCIS to invasive disease was 
greatest.
112
6.2.4.3 EGFR expression in DCIS associated with invasive disease as 
classified by the Van Nuys DCIS Classification system.
Levels of EGFR expression in DCIS associated with invasive disease were 
stratified into groups 1, 2 and 3 of the Van Nuys DCIS Classification system and 
then analysed using the Kruskal-Wallis test. There was no difference in EGFR 
expression between the 3 groups (p = 0.053). Although this was just above the 
level required for statistical significance, after Bonferroni’s correction (which 
adjusts for the fact that multiple comparisons are being made), this p value 
becomes even less significant (pcorr = 0.156). The descriptive statistics for 
expression of EGFR in these groups are shown in Table 16.
VNCS*
Group
N Median Interquartile range
1 12 0.02 0.0032-0.037
2 21 0.051 0.02-0.164
3 14 0.097 0.019-0.315
Total 47
Table 16. Descriptive statistics for EGFR expression in DCIS associated with 
invasive disease according to Van Nuys DCIS Classification system groups 1-3. 
*VNCS = Van Nuys DCIS Classification system.
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6.2.5 EGFR expression in invasive disease
The frequency distribution for the levels o f EGFR expression in the 193 cases 
studied is shown in Figure 25. Only 5 of these lesions had EGFR expression 
above that of the normal breast controls. 97.4% or 188 lesions had a lower than 
normal expression of EGFR.
EGFR expression in invasive disease
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EGFR expression relative to normal n = 193
Figure 25. EGFR X  Normal vs. Frequency for all invasive tumours. Most o f  these 
lesions downregulate EGFR.
114
6.2.6 Frequency distributions of EGFR expression within the spectrum of 
breast cancer
The frequency distributions for EGFR for pure DCIS, DCIS associated with
invasive disease and invasive disease alone, were compared using the Mann-
Whitney U test. This is shown pictorially in Figure 26. There was found to be no
significant difference between the frequency distributions of:
pure DCIS as compared to DCIS with invasion (Mann Whitney U test, p = 0.17),
or
DCIS with invasion compared to pure invasive lesions (Mann Whitney U test, p = 
0.16).
Comparing pure DCIS with pure invasive lesions there is a difference between the 
frequency distributions (Mann Whitney U test, p = 0.009). This may reflect a 
subtle change in EGFR expression as the in situ lesions evolve into invasive 
cancers or it may simply reflect a type 2 statistical error in view of the small 
number of pure in situ tumours involved.
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Frequency Distributions: EGFR 
DCIS with Invasion
Mann-Whitney 
U test, p=0.17
Pure DCIS
Mann-Whitney 
VU test, p=0.16
Pure Invasive
«■—  ■ ■ ■ ►
Mann-Whitney 
U test, p=0.009
Figure 26. The frequency distributions o f growth factor expression for EGFR 
within the spectrum o f breast cancer.
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The components of the Van Nuys DCIS Classification system i.e., nuclear grade 
and necrosis, have been shown to be important predictors of the probability of 
local recurrence after breast conservation treatment for DCIS (36;37;39;43;45-47). 
These data show that EGFR is not overexpressed in pure DCIS when compared 
with samples of normal breast tissue. Furthermore, they suggest that EGFR 
expression is at the same low level irrespective of the aggressiveness of the DCIS. 
The level of expression of EGFR is not significantly different throughout its 
range, as shown by the non-significant p value obtained from performing the 
Kruskal-Wallis one-way analysis of variance. The more aggressive forms of DCIS 
in group 3 of the Van Nuys DCIS Classification system had a similar overall level 
of EGFR expression compared to the less aggressive forms in groups 1 and 2. 
This was true in both the pure DCIS tumours and DCIS associated with invasive 
disease, which has an already proven aggressive phenotype. This would also 
suggest that EGFR is not a major factor in determining the progression of DCIS to 
invasive disease.
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6.3 Results for HER2
6.3.1 HER2 expression in normal breast tissue
HER2 expression was calculated as described in the Materials and methods 
section. The expression in samples obtained from breast reduction specimens is 
shown below in Table 17. The mean expression is 8.56 grains per (mm)2.
Number Range Minimum Maximum Mean
8 8.52 4.42 12.9 8.56
Table 17. HER2 expression in normal breast tissue.
While there were 9 reduction mammoplasty results for EGFR there were only 8 
for HER2 as, following processing for HER2, there was no identifiable breast 
tissue in one of the specimens.
As was done for EGFR, in the analyses below, the level of expression of HER2 is 
expressed relative to the mean level of expression in these normal samples.
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6.3.2 HER2 expression in pure DCIS
The frequency distribution of HER2 in pure DCIS is shown in Figure 27. As with 
EGFR expression, levels of HER2 expression are expressed on a log scale as they 
varied by a factor of several thousand. As shown in figure 26, HER2 expression 
appears to be bimodal. Only 3 tumours have levels lower than normal tissue. The 
first peak, 21 tumours (68%) includes these 3 tumours and has a range of 
expression from 0.07 to 6.8 times normal. The second frequency peak contains 15 
tumours (42%) within which expression ranges from 24 to 180 times normal. In 
total, 92% of tumours overexpress HER2.
HER2 expression in pure DCIS
Log(HER2 X Normal) N = 36
Figure 27. Logio(HER2 XNormal) in pure DCIS vs. Frequency.
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6.3.3 HER2 expression in pure DCIS as classified by the Van Nuys DCIS 
Classification system
Levels of HER2 expression in pure DCIS were stratified into groups 1, 2 and 3 of 
the Van Nuys DCIS Classification system and then analysed using the Kruskal- 
Wallis one-way analysis of variance. The descriptive statistics for expression of 
HER2 in these groups are shown in Table 18.
VNCS*
Group N Median Interquartile range
1 6 1.96 0.28-5.05
2 19 3.64 1.6-6.8
3 11 55.31 39.1-120.5
Total 36
Table 18. Descriptive statistics for HER2 expression in pure DCIS according to 
Van Nuys DCIS Classification system groups 1-3. *VNCS = Van Nuys DCIS 
Classification system.
There was a significant difference in HER2 expression between the 3 groups (p < 
0.0001) by the Kruskal-Wallis test. The Mann-Whitney test was then carried out 
to further explore this highly statistically significant difference:
• No difference was found between groups 1 and 2 (p = 0.16).
• A highly significant difference was found between groups 1 and 3 (p = 0.001).
• A highly significant difference was found between groups 2 and 3 (p < 
0.0001).
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The expression of HER2 in these groups is further presented below in the form of 
a boxplot graph (Figure 28). This clearly shows that although the interquartile 
range for HER2 expression within group 3 of the Van Nuys DCIS Classification 
system is very wide (81.42) there is little overlap with expression in group 2.
HER2 expresssion in pure DCIS 
according to Van Nuys DCIS Classification
3t---------------------------------------------------------------------------------
-2 * — i ~ ■--------------------------1--------------
N = 6 19 11
1 2 3
Van Nuys DCIS Classification System (Groups 1-3)
Figure 28. Expression o f HER2 in pure DCIS according to groups 1-3 o f the Van 
Nuys DCIS Classification system. O denotes outliers within group 2.
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6.3.4 HER2 expression in DCIS associated with invasive disease
The frequency distribution of HER2 in DCIS associated with invasive disease is 
shown in Figure 29. All but 4 o f these tumours overexpress HER2. As with pure 
DCIS, expression of HER2 in these lesions is bimodal. The first peak, 36 tumours 
(76.6%), has a range o f expression from 0.13 to 11.3 times normal, and the second 
has 11 tumours (23.4%) with a range of expression from 29.5 to 324 times normal 
expression.
HER2 expression in DCIS with invasive disease
to------------------------ --------------------------------------------------------
Log(HER2 X Normal) N = 47
Figure 29. HER2 expression in the DCIS component o f  DCIS associated with 
invasive disease vs. Frequency.
The expression of HER2 in the DCIS component was compared with the 
expression in the invasive component of these same tumours using the Wilcoxon 
Signed Rank test with no significant difference in the expression of HER2 in each
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component o f the tumours (p = 0.087). This is shown in figure 30 below.
HER2 expression in the DCIS and invasive 
components of DCIS associated with invasive 
disease
_  2.5 -r-
DCIS component Invasive component
Figure 30. Expression o f HER2 in the DCIS and invasive components o f each 
tumour.
Although overall there appears to be no statistically significant difference between 
these 2 components of the tumours, as is the case with EGFR expression, some 
interesting findings can be found comparing the level of FIER2 expression in the 
in situ versus the invasive components of the tumours of individual patients. In the 
graph above there are clearly some individuals whose expression of HER2 varies 
considerably in the in situ and invasive components. This is shown graphically in 
figure 31 below.
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Difference in HER2 receptors in DCIS
compared to Invasive components
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Figure 31. The size o f the difference in HER2 expression for those tumours with 
both DCIS and invasive components.
The 8 tumours with the largest change in HER2 expression from moving to in situ 
to invasive disease are presented in Table 19 below. The Nottingham Prognostic 
Index for the invasive components of these tumours are also listed. Unfortunately 
only 6 of these 8 scores were available as one tumour was diffuse and the size of 
the other tumour was not recorded.
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Patient ID
EGFR 
receptors in 
DCIS
EGFR receptors in 
invasive 
component
Difference NPI
DCIV39 5.39 217.11 211.72 4.80
DCIV5 264.20 324.22 60.02 6.00
DCIV47 126.02 154.61 28.59 4.60
DCIV52 70.17 31.99 -38.17 4.70
DCIV29 72.52 29.35 -43.18 2.40
DCIV30 90.93 36.68 -54.25 N/A
DCIV37 324.19 246.57 -77.62 N/A
DCIV14 183.27 6.85 -176.42 4.70
Table 19. The 8 tumours with the greatest change in HER2 expression between 
the in situ and invasive components. A positive value implies an increase in HER2 
expression and a negative value a decrease. NPI = Nottingham Prognostic Index. 
N/A = Not available.
The NPI for 34 of the 47 invasive tumours was available, with a median of 4.40 
(interquartile range = 1.64). For the 6 tumours with the largest change in HER2 
expression which had an NPI available the median here is 4.70 (interquartile 
range = 1.05). Using the Mann-Whitney U test there was no statistically 
significant difference in the NPI between those tumours that had the largest 
difference in HER2 expression in the in situ compared to the invasive components 
of the tumour and the other invasive tumours that had associated DCIS (p=0.31).
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However, as with EGFR, those tumours that had a large change in HER2 
expression between the in situ and invasive components did appear to do badly. 
Patient DCIV39 with the largest such increase in HER2 expression between the in 
situ and invasive components in this series had a very aggressive tumour with 2 of 
2 lymph nodes tested being positive. A year later she unfortunately developed a 
local recurrence treated by mastectomy but developed liver metastases the 
following year.
Patient DCIV5 had a large 50mm tumour with a positive lymph node (1 of 4) and 
died from metastatic breast cancer less than 2 years from the time of diagnosis. 
Patient DCIV47 had a node positive breast cancer which recurred in the chest wall 
post mastectomy and later recurred in the axilla.
Patient DCIV52 had a ductal carcinoma with an NPI of 4.7 which was node 
negative (0 out of 6sampled). Unfortunately she died 7 years after diagnosis from 
metastatic breast cancer.
Patient DCIV29 had a node negative breast cancer with an NPI of 2.4 and was 
alive and well at last follow up (June 1997, 9 years after diagnosis).
Patient DCIV30 had a large 120mm tumour excised which was Grade 3 but did 
not have any lymph nodes found on sampling. She unfortunately died from 
metastatic breast cancer within a year of diagnosis.
Patient DCIV37 is the same patient with the largest increase in EGFR expression 
between the in situ and invasive components (page 108). She had a very 
aggressive tumour with 6 out of 6 lymph nodes tested being positive. The tumour 
was multifocal and there was widespread lymphatic permeation and soft tissue 
metastases in the axilla. She also died just 2 years after diagnosis of breast cancer.
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Patient DCIV14 had a 35mm, node negative breast cancer treated by mastectomy 
and axillary node clearance with an NPI of 4.70. Unfortunately she also 
succumbed to metastatic breast cancer 5 years after diagnosis.
As highlighted earlier, these do not represent consecutive cases and are small 
numbers. Nevertheless, it is interesting to note these individual cases of clearly 
aggressive tumours where the change in expression from DCIS to invasive disease 
was greatest. This perhaps indicates an area for future work as a means of 
identifying aggressive forms of breast cancer where there is an identifiable in situ 
component.
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6.3.5 HER2 expression in DCIS associated with invasive disease as classified 
by the Van Nuys DCIS Classification system
Levels of HER2 expression in DCIS associated with invasive disease were 
stratified into groups 1, 2 and 3 of the Van Nuys DCIS Classification system and 
then analysed using the Kruskal-Wallis test. The descriptive statistics for 
expression of HER2 in these groups are shown in Table 20.
VNCS*
Group N Median Interquartile range
1 13 2.88 1.42-5.55
2 18 4.45 2.5-29.7
3 16 3.10 1.2-71.9
Total 47
Table 20. Descriptive statistics for HER2 expression in pure DCIS according to 
Van Nuys DCIS Classification system groups 1-3. *VNCS = Van Nuys DCIS 
Classification system.
There was no difference in HER2 expression between the 3 groups (p = 0.4) using 
the Kruskal-Wallis test.
The expression of HER2 in these groups is further presented below in the form of 
a boxplot graph (Figure 32).
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HER2 expression in DCIS associated with invasive 
disease according to Van Nuys DCIS Classification
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Figure 32. Expression o f HER2 in DCIS associated with invasive disease 
according to groups 1-3 o f the Van Nuys DCIS Classification system, o denotes 
outliers within the groups.
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6.3.6 HER2 expression in invasive disease
The frequency distribution for the levels of HER2 expression in the 177 cases 
studied is shown in Figure 33. As with the expression of HER2 in pure DCIS and 
in DCIS associated with invasive disease, this distribution is again bimodal, with a 
nadir at about 15 times normal expression level. Twenty-six tumours (15%) had 
levels lower than those in the normal breast controls, of which only 2 had no 
detectable expression of HER2. Forty-one cases (23%) had levels more than 15 
times normal. Previous studies by this group have shown that a level of 15 times 
normal expression corresponds to gene amplification (1). The remaining 110 
tumours (62%) showed levels of HER2 expression between 1 and 15 times 
normal.
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HER2 expression in invasive disease
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Figure 33. Logw(HER2 X  Normal) vs. Frequency for all invasive tumours.
This shows the 3 groups of HER2 expression in invasive disease:
Group A where expression is less than that of normal breast tissue.
Group B where expression is between normal and 15 times normal 
expression.
Group C where expression is greater than 15 times normal expression.
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6.3.7 Frequency distributions of HER2 within the spectrum of breast cancer
The frequency distributions for HER2 in pure DCIS, DCIS associated with 
invasive disease and invasive disease alone, were compared using the Mann- 
Whitney U test. This is shown pictorially in Figure 34. There was found to be no 
significant difference between the frequency distributions of:
- pure DCIS as compared to DCIS with invasion (Mann Whitney U test, p = 0.16), 
or
- DCIS with invasion compared to pure invasive lesions (Mann Whitney U test, p 
= 0.91).
- pure DCIS compared to pure invasive lesions (Mann Whitney U test, p = 0.07).
Frequency Distributions: HER2 
DCIS with Invasion
Mann-Whitney 
U test, p=0.16
Pure DCIS
Mann-Whitney
U test, p=0.91
Pure Invasive
Mann-Whitney 
U test, p=0.07
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Figure 34. The frequency distributions o f growth factor expression for HER2 
within the spectrum of breast cancer.
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6.3.8 Patient and tumour characteristics for invasive tumours in which HER2 
was measured
The patient and tumour characteristics for the invasive tumours where HER2 was 
measured have been compared to those of the unselected tumour population. 
These characteristics are presented in Table 21.
The comparative group is comprised of cases treated in the same surgical unit as 
the selected group. These were not included in the study because frozen tissue was 
not available for these tumours. As can be seen, there is no significant difference 
between the 2 groups in terms of patient age, grade or size of tumour, involved 
nodes or oestrogen receptor status.
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Overall cases 
Patient age 
Median 
Grade
1
2
3
Total
Tumour Size
<21 mm 
21-50 mm 
>50 mm 
Total 
Involved 
0
1-3
>3
Total
ER Status
Negative
Positive
Total
Dataset used in this study: 
1984 to August 1993
n =177
62.28
(%)
25 (14)
64 (36)
87 (50)
176
70 (40)
81 (47)
22 (13)
173
74 (48)
53 (35)
26 (17)
153
Unselected comparative 
group:
1984 to 1994
n = 218
61.24
<%)
15(21)
24 (33)
34 (46)
73
94 (48)
91 (47)
9(5)
194
97 (52)
62 (33)
28(15)
187
55 (44) 
71 (56) 
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59 (40) 
87 (60) 
146
Table 21. Patient and tumour characteristics for the 177 cases in this study and 
the characteristics o f the unselected data set for comparison.
6.3.9 Survival analysis
6.3.9.1 Analysis with HER2 expression considered as a single variable
Initial survival analysis was carried out examining HER2 expression alone as a 
prognostic variable. Univariate analysis of disease specific survival (Figure 35) 
showed prognosis to be significantly worse in groups A and C compared to group 
B (overall Chi square = 21.27, df = 2, p < 0.00005). There was no significant 
difference between outcome in groups A (below normal) and C (amplified) (Chi 
square = 0.13, df = 1, p = 0.72). The significantly poorer outcome in groups A and 
C applied to both overall survival (global Chi square = 20.74, df = 2, p < 0.00005) 
and recurrence free survival (global Chi square = 19.65, df = 2, p = 0.0001). This 
relationship applied in both node negative and node positive tumours.
Disease specific survival and HER2 expression
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Figure 35. Disease specific survival and HER2 expression.
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6.3.9.2 Multivariate analysis comparing disease free survival in these 3 
groups against known pathological variable and the Nottingham Prognostic 
Index.
Multivariate analysis showed that the survival effect of HER2 expression was 
independent of pathological variables and the Nottingham Prognostic Index (see 
section 1.4.2.2). Dividing patients according to the Nottingham prognostic index, 
those in NPI group 1 with between normal and amplified levels o f HER2 
expression had a 5-year survival of 92%. But only 79% of patients with amplified 
or downregulated HER2 levels survived 5 years. This is shown below in Figures 
36-38 and Table 22.
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Figure 36. Survival for patients in NPI group 1 according to HER2 expression.
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Survival for patients in NPI Group 2
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Figure 37. Survival for patients in NPI group 2 according to HER2 expression.
Similarly, for patients in NPI group 2, 66% of those with HER2 levels of 
expression between normal and amplified levels survived 5 years while only 29% 
of those with either very low or very high levels of HER2 expression survived 5 
years.
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Survival for patients in NPI Group 3
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Figure 38. Survival in NPI group 3 according to HER2 expression.
HER2 expression
Group B Group A & C
NPI Group 1 92% 79%
NPI Group 2 66% 29%
NPI Group 3 29% 20%
Table 22. Five year survival for patients in NPI Groups 1-3 according to level o f  
HER2 expression.
Group A (26 tumours, 15%) -  Less than normal levels of expression.
Group B (110 tumours, 62%) -  Between normal and 15 X Normal.
Group C (41 tumours, 23%) -  More than 15 X Normal levels of expression.
138
63.9.3 Cox’s proportional hazards model
The statistical analyses above could be criticised as the division of HER2 
expression into 3 groups is artificial. For this reason, more complicated statistics 
were then carried out. The inclusion of quadratic and cubic terms of HER2 was 
done to make full use of the quantitative information available from 
radioimmunohistochemistry without making any assumptions as to the nature of 
the relationship between HER2 and outcome. The results of this analysis 
demonstrate a continuous relationship, whereby the best prognosis was associated 
with intermediate levels of HER2 expression. Expression levels at both the lower 
and upper ends of the distribution are associated with poorer outcome.
The model which fits the data includes a quadratic term to allow for the fact that 
relative hazard increases with either decreasing or increasing levels of HER2 from 
an optimal level which is at a HER2 value of about 5.7. The inclusion of a cubic 
term allows for asymmetry in change, e.g. halving the HER2 level does not have 
the same effect as doubling the HER2 level as the level moves away from the 
optimal. The best fitting hazard function is:
h(t) = h(to) exp(-l.8790*log(b2+l) + 0.7159*[log(b2+l)]2 -  0.0673*[log(b2+l)]3 ).
Where b2 = the HER2 level expressed relative to normal breast. The function is 
shown in Table 23.
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Component* LR d.f. p-value
linear 8.2 1 0.001
add quadratic 7.0 1 0.001
add cubic 6.2 1 0.001
Table 23. Model based only on the quantitative level o f HER2.
*in respect of the quadratic and cubic terms, terms were added to a model 
which included terms in previous rows and the p-value records the gain 
from each addition.
The prognostic effect of HER2 when considered in isolation is complex, in that 
the best outcome is associated with an intermediate level of expression. Prognosis 
then becomes worse at both higher and lower levels of expression, the relative risk 
being about 3.5 for a tumour with a level of 0.1 x normal, and about 4 for a tumour 
with a value of lOOx normal. So, although amplified tumours (as identified by 
expression level above 15x normal) overall do worse than unamplified ones, 
tumours with very low levels of expression do very nearly as poorly as those with 
amplification. This relationship does not suggest the presence of expression 
thresholds, for instance associated with HER2 amplification, but rather that 
outcome is associated with HER2 expression in a continuous fashion. This 
approach does not specifically test the possibility that there are thresholds at 
which the outcome changes, but we have preferred not to do so in order to avoid 
both generating and testing hypotheses within the same dataset.
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Figure 39. Survival function for HER2 as an isolated variable. HER2 expression 
is given as a multiple o f mean expression in normal breast. Relative hazard is 
expressed with respect to that at the best prognosis level o f 5.7 times normal 
HER2 expression. Note that prognosis is worse in tumours with both higher and 
lower levels o f HER2 than this.
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6.3.9.4 Analysis with size, nodes and grade included with HER2 expression.
Subsequent analysis was carried out to see if controlling for the standard 
pathological variables of tumour grade, tumour size and nodal status altered the 
relationship to prognosis, which we have just described for HER2. This analysis 
indicates that the basic nature of the relationship between HER2 and prognosis 
was not altered by the addition of the other variables.
Stepwise fitting of a model which includes histological grade, macroscopic 
tumour size and number of nodes involved indicated that all three variables are 
required. If the linear, quadratic and cubic terms in HER2 are also included, Grade 
is the only variable which is not included in a stepwise fit (p=0.2). The best fitting 
hazard function is
h(t) = h(to) exp(0.1023*nodes + 0.0276*size -  2.806* [log(b2+l] + 
1.0656*[log(b2+l)]2 -  0.1008*[log(b2+l)]3).
The effect of varying size and the number of nodes on the hazard function for 
HER2 is illustrated in Figure 38. Thus, there is evidence that there is information 
about the risk of dying in the quantitative level of HER2 over and above that 
contained in the standard pathological variables. Furthermore, with the inclusion 
of the HER2 terms, tumour grade becomes redundant, i.e. the information 
contained in the ‘grade’ variable is contained in the level of HER2.
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Figure 40. Example o f survival function for HER2 when allowance is made for 
pathological variables, in this case nodal status. As in Figure 33, HER2 
expression is given as a multiple o f mean expression in normal breast. Relative 
hazard, where HER2 o f 5.7 times normal has hazard o f 1, is shown for patients 
with no axillary nodes involved, and for those with 10 nodes involved. Although 
these two groups have differing overall prognoses, the relationship between 
HER2 expression and outcome persists within each group.
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6.3.9.5 Analysis with above variables as well as ER
Within this series, oestrogen receptor status is the single most powerful prognostic 
factor in its own right. This is clearly indicated by the size of the gain from its 
inclusion in a hazard function. (LR gain=33.6 (1 d.f.) pO.OOl ). It is also clear 
that there is a strong linkage between ER and HER2, with the ER negative 
tumours being clustered in the low and high expression tails of the HER2 
frequency distribution (Figure 39). Fitting of ER status and the standard 
pathological variables (number of involved nodes, macroscopic tumour size and 
histological grade) in a survival analysis results in ER status and size being the 
only predictors required. The relationship between ER status and HER2 displayed 
in Figure 29 indicates that separate hazard functions are required for ER positive 
and negative groups. Adding HER2 as a variable in the ER positive group 
produces no significant effect (p=0.6). A similar finding is obtained for the ER 
negative group (p = 0.2). These results are unchanged if adjustment for size 
differences of tumours is made. Thus, the models which are suggested above as 
having prognostic power when the ER status of patients is ignored, lose that 
power when fitted separately to the ER positive and ER negative groups.
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Figure 41. HER2 expression in oestrogen receptor positive and negative 
subgroups, n = 55 for the ER- group and n = 71 for the ER+ group. Note that 
the ER- cases congregate at the low and high end o f the HER2 expression 
spectrum (poor prognosis) whilst the ER+ cases tend to have intermediate HER2 
levels and a correspondingly good prognosis.
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SECTION 7 DISCUSSION
7.1 Growth factor expression in “normal” breast tissue
This study has used specimens of histologically normal breast which were 
obtained from 9 reduction mammoplasty procedures. It can be reasonably argued 
that tissue from reduction mammoplasty specimens is not the ideal control for 
breast cancer specimens. The indication for the operation, i.e. very large breasts, 
may be a reflection of deregulation of growth factor receptors. There is to our 
knowledge no evidence to suggest that this is so. Reduction mammoplasty 
patients are also younger than the majority of cancer patients but it is very rare for 
completely normal breast tissue to be removed from middle aged or older women. 
In an attempt to use other “normal” breast tissue, areas of normal breast tissue 
within the tumour tissue studied were measured for these growth factors. These 
areas showed similar receptor expression to that of the control specimens; 
however, these areas may be subject to some of the genetic changes that have 
resulted in the adjacent pathology.
As can be appreciated, it is extremely difficult to obtain normal breast tissue for 
use as controls. It can even be difficult to define what constitutes normal control 
tissue for breast cancer tissue. Accepting these arguments we have used tissue 
removed for purposes other than cancer treatment which histologically shows no 
sign of disease. Since the consensus origin of breast carcinoma is at the level of 
the terminal ductolobular unit, lobular tissue from the reduction mammoplasty 
specimens was used for our control measurements.
There has been a tendency in most studies of growth factor expression to regard 
any expression as overexpression. We believe that it is crucial, especially in these
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sensitive and quantitative analyses such as has been used here, to attempt to assess 
expression relative to that in normal tissues.
7.2 Radioimmunohistochemistry and growth factor expression in DCIS
This study represents one of a very few investigations into EGFR expression in 
DCIS. As described in section 3.2.2, the need to use frozen tissue does make it 
more difficult and may explain the lack of studies into EGFR expression in DCIS. 
Radioimmunohistochemistry combines the objective quantification of ligand 
binding studies with the tissue specificity of conventional immunohistochemistry. 
Using this technique, we have previously shown that the vast majority of primary 
breast cancers overexpress HER2 and downregulate EGFR, relative to normal 
breast tissue (2). We have shown that in the 3 groups of tumours studied here 
(pure DCIS, DCIS associated with invasive disease and invasive disease alone), 
there is a high level of HER2 overexpression and EGFR downregulation when 
compared to normal breast tissue.
There was no significant difference in expression of either of these growth factor 
receptors in the pure DCIS group compared to the group with DCIS in association 
with invasive disease, nor was there a significant difference between the group 
with DCIS in association with invasive disease and the purely invasive group. 
There was, however, a significant difference between the expression of EGFR in 
the pure DCIS group compared to the invasive group (p = 0.009). There was also 
a trend to significance in the expression of HER2 between the pure DCIS group 
and the invasive group (p = 0.07). This may represent a subtle change in the 
expression of these growth factor receptors as in situ lesions become invasive. 
This may imply that even this sensitive radioimmunohistochemical technique is
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unable to detect and display a very subtle change in expression of these growth 
factor receptors in these 2 tumour populations. While this finding of a trend to 
significance in these 2 tumour populations may simply be a statistical error due to 
the small numbers involved, this may represent an area for future work into the 
intricate workings of this family of growth factor receptors in breast cancer. 
Comparing the 2 groups of DCIS, the lesions found adjacent to invasive cancers 
have a proven progressive genotype whereas the pure DCIS group may or may not 
subsequently progress. The similarities in expression between these 2 groups 
suggest that these changes in growth factor expression are not a predictor of 
progression of DCIS to frank malignancy. Indeed, by the time of development of 
in situ breast cancer, HER2 upregulation and EGFR downregulation are almost 
universally present. It is interesting, however, that those tumours that undergo a 
large change in EGFR and also HER2 expression between the in situ and invasive 
components had very aggressive invasive tumours. The intricacies involved in 
receptor binding and interactions between these 2 members of the Type 1 growth 
factor receptor family, and indeed the other members of the family, are 
enormously complex and at present not well understood. Larger studies would be 
required to show whether a large change in expression of these receptors between 
in situ disease in association with invasive disease and the invasive components of 
the same tumours could indeed act as a prognostic indicator and so allow those 
tumours to be treated more aggressively from the beginning.
We know from autopsy studies on women dying from causes other than breast 
cancer that proliferative disease without atypia, atypical ductal hyperplasia and 
ductal carcinoma in situ (DCIS) are progressively less frequent (15). Accurate
148
quantification of earlier lesions such as proliferative disease without atypia and 
atypical hyperplasia may help determine which lesions are the specific precursors 
of in situ carcinoma.
On the other hand, numerous studies, including our own (2), have consistently 
shown HER2 to be overexpressed in a large proportion of invasive breast cancers 
and conferring a poorer prognosis. We have shown here that in the earlier stages 
of breast cancer, the same changes in expression of these 2 growth factors can be 
found. These results imply that the disregulation of these growth factor receptors 
is an early event in breast carcinogenesis. Members of this growth factor receptor 
family are known to form heterodimers which can result in an increase in kinase 
activity. While it is interesting to speculate that receptor interaction or 
internalisation explains the relative ability to detect these receptors, the precise 
mechanisms involved in the relative changes in the expression of these growth 
factor receptors in the spectrum of breast cancer is unclear.
Overexpression of HER2 occurs as a result of increased gene transcription, with 
or without gene amplification. Conventional methods of measuring HER2 are far 
less able to detect expression of HER2 at sub-amplification levels of 
overexpression. This sensitive radioimmunohistochemical method allows very 
low levels of expression to be detected and allows the cell type expressing the 
receptor to be identified. Although labour intensive, sensitive methods such as this 
will in time help to unravel the complex interactions between members of this 
type 1 growth factor receptor family. Similarly, if it is indeed true that increased 
transcription precedes gene amplification in the natural history of the disease, then 
identification of early, small increases in expression may prove important.
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7.3 Growth factor expression in DCIS stratified according to the Van Nuys 
DCIS Classification system
When DCIS is stratified according to the Van Nuys DCIS Classification system 
there was no difference in growth factor expression according to the different 
groups apart from that of HER2 in pure DCIS. The more aggressive forms of 
DCIS according to this classification system had a significantly higher level of 
expression than the less aggressive forms. This may imply that HER2 expression 
may play a part in the biology of aggressive DCIS. This difference in expression 
according to Van Nuys DCIS Classification system groups is then lost when 
analysing DCIS associated with invasive disease. While the number of lesions 
analysed by this labour intensive method was small it is interesting to suggest that 
once progression to invasion occurs, the role played by HER2 is less important. 
This however would not be consistent with our survival analysis discussed below.
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7.4 Molecular biology of breast cancer progression
As is believed to be the case with most other cancers, breast cancer development 
is thought to have its origin in one cell which through a series of events becomes 
malignant. The development of breast cancer involves many types of genes that 
need to be activated or inactivated in order to promote malignancy. The sequential 
steps in gene alterations with respect to tumour progression are not clear. Indeed 
the events involved in the progression of breast cancer are far less well understood 
than the adenoma-carcinoma sequence of colorectal cancer. Genetic changes in 
presumed precursor stages of breast cancer such as ductal hyperplasia, atypical 
ductal hyperplasia and DCIS have been studied. Loss of heterozygosity in 
hyperplastic disease has been detected and this suggests that these lesions are 
benign neoplasms and that inactivation of tumour suppressor genes play a role in 
their development (310). Studies of DCIS and more advanced lesions show a 
complex and poorly understood pattern of genetic alterations. Most genetic 
defects detected in invasive cancer are already present in DCIS (226;310-314). 
This is in keeping with our findings presented here. Gene amplifications appear to 
be a late event in tumour progression as they are mainly found in tumour cells that 
have acquired genomic instability and tolerate its presence (315). None of the 
oncogenes located at amplified chromosomal regions in invasive breast cancer are 
amplified in benign breast disease (316-318). It is generally agreed that oncogene 
amplification is not an early event in the multistep carcinogenesis of breast cancer 
but emerges in DCIS (315;319). It is also suggested that oncogene mediated 
proliferation is predominantly at the intermediate state of breast cancer
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development and is not of obvious importance in the progression to metastatic 
disease (315;319).
Our findings are in keeping with general opinion as suggested by the literature. 
We find that the changes in EGFR and HER2 expression are already present by 
the time DCIS has developed. Although a frozen tissue bank of earlier benign 
lesions would be difficult to establish and would likely require multicentre 
collaboration, this sensitive and quantitative method may provide further insight 
into the role that these growth factor receptors play in the progression from benign 
neoplasms to more advanced disease.
7.5 Radioimmunohistochemistry and growth factor expression in invasive 
breast cancer
7.5.1 EGFR
This group has previously shown using radioimmunohistochemistry that EGFR 
overexpression relative to normal breast epithelial cells is rare (2). This is in 
keeping with work done by Slamon et al (221) who reported that EGFR gene 
amplification was found in only 4 of 189 breast cancers studied by Southern 
blotting. It seems unlikely therefore that EGFR abnormalities, at least in 
expression levels, have an oncogenic influence in breast cancer.
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7.5.2 HER2
This work extends our previous study of HER2 expression in invasive breast 
cancer to a larger population of tumours, and analyses the role of expression in the 
prediction of patient outcome. This reinforces our earlier suggestions that:
1) 85% of breast cancers overexpress HER2, not only the 25% with gene 
amplification;
2) expression of HER2 varies by more than three orders of magnitude;
3) the frequency distribution for HER2 expression levels shows two distinct 
populations.
In addition, we now suggest that:
1) there is a strong, continuous relationship between HER2 expression and 
prognosis;
2) both very low and very high HER2 expressing tumours have poor outcome;
3) this relationship to prognosis remains significant after the introduction of 
standard pathological variables into the analysis;
HER2 expression level therefore encodes more information than gene 
amplification alone.
The most striking finding of this study is that poor survival is experienced by 
breast cancer patients with low as well as high HER2 expressing tumours. 
Previous studies have suggested that there is a group of breast cancer patients with 
low HER2 expression and a poor prognosis. Dittadi and co-workers (320) 
measured HER2 in an ELISA system on 105 breast cancer specimens and divided 
the cases into quartiles based on the ranked expression. The upper and lower 
quartiles were reported to have a significantly shorter relapse free survival than
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those cases with intermediate expression (median follow-up of 30 months). In 
another ELISA based study, Koscielny and co-workers indicated that tumours 
with low HER2 values (110 out of 1062 cases studied) were more likely to be 
oestrogen and progesterone receptor negative (321) and hypothesised that this 
represented a poor prognosis group. A further report focusing on a subset of these 
patients (322) indicated that the patients with low HER2 expression did indeed 
have a significantly poorer prognosis. Expression was assessed in 117 primary 
breast carcinomas and cases were categorised into groups having significantly 
lower expression than normal (8.5%), within the normal range of expression 
(77%) or overexpression (14.5%). Four of the 10 patients with low expression 
developed metastases (median follow-up 38 months) whereas only 8 of the 90 
patients with normal expression relapsed over this period.
Recently there has been active debate regarding the relationship of low HER2 
expression and poor prognosis, with a report by Ferrero-Pous (323) indicating 
irreproducibility of Koscielny's findings. Our data are in keeping with the reports 
of Kosceilny and Dittadi (320-322), but we have been able to assess HER2 as a 
continuous variable rather than assigning arbitrary cut points to the data. 
Furthermore, both of the studies mentioned above use an ELISA based approach 
to assess HER2 expression, requiring tissue homogenization prior to analysis. 
Using relatively large amounts of tissue these methods potentially average out 
inconsistency due to tumour heterogeneity, but there is an inherent problem with 
the disruption of tissue architecture resulting in variable non-tumour 
contamination in the measured sample.
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Attempts in our laboratory using conventional immunohistochemistry to identify 
the poor prognosis low HER2 expressing group were unsuccessful. 
Immunohistochemical measurements on paraffin sections, indicated that only 30% 
of cases with the highest level of expression gave positive signals (data not 
shown). In frozen sections, immunoperoxidase labelling with a streptavidin biotin 
system and the ICR12 monoclonal antibody (307) demonstrated positive HER2 
labelling in greater than 90% of cases, however, we were unable to demonstrate a 
significantly poorer prognosis associated with the lowest expressers using this 
method due to a lack of quantitative accuracy in tumours with very low levels of 
HER2 expression (data not shown).
The mechanism behind the aggressive nature of low HER2 expressing tumours is 
not clear. The majority of these cases were known to be oestrogen receptor 
negative and thus less likely to respond to hormonal treatment whereas the cases 
with intermediate expression were more likely to be oestrogen receptor positive 
receiving the full benefit of adjuvant hormonal therapy. Previously, we have 
demonstrated an inverse relationship between epidermal growth factor receptor 
expression and HER2 expression in tumours without amplification of the HER2 
gene (2), with the low expressing HER2 tumours more likely to express the 
epidermal growth factor receptor. This may provide a HER2 independent 
mechanism for proliferation in response to the stimulation of an epidermal growth 
factor mitogenic pathway. The clinical significance of low HER2 expression 
should be addressed with a larger study to assess the potential predictive value of 
response to hormonal or chemotherapy regimens.
In contrast to the relatively novel finding of poor survival associated with low
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HER2 expression, it has been known for more than a decade that the 25 to 30% of 
patients with the highest levels of HER2, or those with amplification of the HER2 
gene, have a poor outlook, although there remains a high level of inter-study 
variation (324). Our data support this finding and we show that patients with 
high HER2 expressing tumours have up to a 4 fold greater relative risk of dying 
from a breast cancer related cause than patients with optimal HER2 expression. 
While there has been a loss of interest in prognostic factors in breast cancer in 
recent years, there has been a resurgence in interest in measurement of HER2 as a 
predictive factor for Tamoxifen and chemotherapy regimens 
(252;283;296;298;325;326). Furthermore, the application of receptor targeted 
therapies to appropriate patients is dependent on HER2 measurement. The 
methods that are currently being used for these indications involve measurement 
of the HER2 gene copy number or immunohistochemical assessment of HER2 in 
paraffin sections. Neither method is quantitative, both give results for less than 
30% of cases. There have been significant advances in standardization of 
conventional immunohistochemical methods, particularly with the development of 
dedicated FDA approved tests (HercepTest® from DAKO). However, 
conventional immunohistochemical methods remain subjective and dependent on 
the assignation of arbitrary cutpoints that are determined in part by the sensitivity 
of the techniques themselves rather than by the biology of the disease. 
Radioimmunohistochemistry however, gives quantitative results for all cases, and 
from examination of this relatively small retrospective cohort of breast cancer 
cases, the data do suggest that the relationship between HER2 expression and 
survival is a continuous one and can be best defined using quantitative
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methodology. As the patients making up this study underwent a variety of 
treatment regimens, the observed survival effect is likely to be due to a 
combination of factors with the positive effect of treatment regimens being 
superimposed upon the pure prognostic component. This may in part explain the 
very strong apparent prognostic effect of oestrogen receptor in this data set. This 
strong effect omits not only HER2 as a prognostic factor, but also nodal status and 
histological grade, when it is included in the model. This finding does not exclude 
a prognostic role for these factors, but indicates that within this particular patient 
group they have lower predictive value than ER. In other patient groups, where 
the effect of ER upon outcome is typically less marked, these other factors might 
have a greater role in the overall prognostic model. Nor does the powerful effect 
of ER alter the nature of the relationship between HER2 and prognosis when 
considered in isolation.
Application of radioimmunohistochemistry to a large cohort of breast cancer 
patients is warranted in order to assess whether there are continuous relationships 
between HER2 levels and responses to endocrine therapy, chemotherapy and 
targeted therapies or whether there are critical thresholds of expression that 
separate responders and non-responders. Once these relationships have been 
defined, they can be used as templates to design assays with greater clinical 
applicability.
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7.6 Implications to proposed new treatment modalities
The EGFR is a proposed target for treatment of other cancers such as head and 
neck cancers. Monoclonal antibodies such as cetuximab (IMC-C225) which have 
a higher affinity for the EGFR than endogenous ligands have been developed to 
target the EGFR. This method has been promoted as a means of specifically 
targeting tumour cells (327). Our results suggest that this approach is unlikely to 
work in breast cancer as the vast majority of breast cancers downregulate EGFR. 
Only a small proportion (less than 5%) of tumours studied had a higher level of 
EGFR expression compared to normal breast tissue. This implies that for breast 
cancer tissue there would be no such targeting specificity to tumour cells.
The clinical results with the monoclonal antibody to HER2 [Herceptin, 
(trastuzumab)] hold significant promise. This monoclonal antibody has shown 
promising results in HER2 overexpressing metastatic breast cancer. Our data 
suggest that the proportion of tumours overexpressing HER2 is considerably 
higher than that detected by non-quantitative methods. It is tempting, therefore, to 
suggest that the potential use for Herceptin may be considerably wider than the 
30% or so of currently detectable HER2 overexpressers. Conversely, gene therapy 
or receptor targeting approaches directed at HER2 pathways may not be desirable 
as complete abolition of HER2 expression may have an adverse effect on tumour 
progression.
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Counts for pure DCIS - HER2
Patient ID Batch Date Formula/mm2/hr/100 Conversion Factor Receptors Normal R HER2XN
Pure2 04/02/1997 10.283 19.66 202.172 8.557 23.626
Pure3 04/02/1997 2.203 19.66 43.304 8.557 5.061
Pure5 04/02/1997 0.030 19.66 0.593 8.557 0.069
Pure6 04/02/1997 2.006 19.66 39.439 8.557 4.609
Pure7 04/02/1997 2.797 19.66 54.981 8.557 6.425
Pure8 04/02/1997 2.338 19.66 45.963 8.557 5.371
Pure9 22/12/1997 0.791 69.10 54.677 8.557 6.390
Purel 1 22/12/1997 4.031 69.10 278.534 8.557 32.550
Pure13 22/12/1997 6.195 69.10 428.050 8.557 50.023
Purel 4 22/12/1997 22.351 69.10 1544.431 8.557 180.485
Purel 5 22/12/1997 0.359 69.10 24.798 8.557 2.898
Purel 6 23/12/1997 19.905 69.10 1375.469 8.557 160.740
Purel 7 22/12/1997 0.549 69.10 37.939 8.557 4.434
Purel 8 22/12/1997 0.197 69.10 13.591 8.557 1.588
Purel 9 22/12/1997 0.450 69.10 31.125 8.557 3.637
Pure20 22/12/1997 0.327 69.10 22.603 8.557 2.641
Pure21 22/12/1997 0.844 69.10 58.315 8.557 6.815
Pure22 22/12/1997 0.158 69.10 10.933 8.557 1.278
Pure27 22/12/1997 14.919 69.10 1030.882 8.557 120.471
Pure23 22/12/1997 0.182 69.10 12.547 8.557 1.466
Pure24 22/12/1997 4.420 69.10 305.434 8.557 35.694
Pure25 10/06/1998 0.431 64.30 27.726 8.557 3.240
Pure26 10/06/1998 5.197 64.30 334.189 8.557 39.054
Pure28 10/06/1998 3.438 64.30 221.045 8.557 25.832
Pure29 10/06/1998 14.347 64.30 922.502 8.557 107.805
Pure38 10/06/1998 0.047 64.30 3.052 8.557 0.357
Pure39 10/06/1998 7.361 64.30 473.282 8.557 55.309
Pure40 10/06/1998 12.723 64.30 818.110 8.557 95.606
Pure41 10/06/1998 0.306 64.30 19.679 8.557 2.300
Pure43 10/06/1998 16.976 64.30 1091.575 8.557 127.563
Pure44 10/06/1998 0.168 64.30 10.785 8.557 1.260
Pure45 10/06/1998 0.468 64.30 30.109 8.557 3.519
Pure46 10/06/1998 16.697 64.30 1073.610 8.557 125.464
Pure47 10/06/1998 5.944 64.30 382.174 8.557 44.662
Pure48 10/06/1998 0.135 64.30 8.676 8.557 1.014
Pure50 10/06/1998 0.026 64.30 1.653 8.557 0.193
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APPENDIX III. Counts for DCIS for DCIS in association with invasive disease - EGFR
Patient ID Batch Date Formula Formula/hr/100 A431 Grains % A431 Normal EGFR EGFRXN
DCIV1 13/04/1993 3731.852 0.381 144.1 0.264 7.614 0.035
DCIV2 13/04/1993 15930.709 1.626 144.1 1.128 7.614 0.148
DCIV3 13/04/1993 12038.714 1.228 144.1 0.852 7.614 0.112
DCIV4 13/04/1993 6317.754 0.645 144.1 0.447 7.614 0.059
DCIV5 13/04/1993 28004.800 2.858 144.1 1.983 7.614 0.260
DCIV6 04/05/1993 20416.292 1.047 140.0 0.748 7.614 0.098
DCIV7 04/05/1993 13196.836 5.175 140.0 3.697 7.614 0.486
DCIV8 11/05/1993 6480.716 0.453 121.0 0.375 7.614 0.049
DCIV9 06/05/1993 -2696.698 -0.138 135.3 -0.102 7.614 -0.013
DCIV10 08/06/1993 20431.183 1.419 206.0 0.689 7.614 0.090
DCIV11 04/05/1993 6501.520 0.333 140.0 0.238 7.614 0.031
DCIV12 04/05/1993 2016.477 0.103 140.0 0.074 7.614 0.010
DCIV13 08/06/1993 41706.551 5.713 206.0 2.773 7.614 0.364
DCIV14 13/04/1993 5216.543 0.532 144.1 0.369 7.614 0.049
DCIV15 08/06/1993 3584.330 0.491 206.0 0.238 7.614 0.031
DCIV16 08/06/1993 596.342 0.041 206.0 0.020 7.614 0.003
DCIV17 08/06/1993 28076.556 1.950 206.0 0.946 7.614 0.124
DCIV18 08/06/1993 5556.558 0.386 206.0 0.187 7.614 0.025
DCIV19 04/05/1993 7242.251 0.371 140.0 0.265 7.614 0.035
DCIV20 08/06/1995 1778.372 0.106 152.1 0.070 7.614 0.009
DCIV21 08/06/1995 7930.982 0.475 152.1 0.312 7.614 0.041
DCIV22 08/06/1995 -6116.914 -0.366 152.1 -0.241 7.614 -0.032
DCIV23 05/06/1995 16563.922 1.146 121.3 0.945 7.614 0.124
DCIV24 05/06/1995 446.822 0.172 121.3 0.142 7.614 0.019
DCIV25 06/06/1995 4367.949 0.302 131.6 0.230 7.614 0.030
DCIV26 06/06/1995 11828.076 4.549 131.6 3.457 7.614 0.454
DCIV27 06/06/1995 92.846 0.036 131.6 0.027 7.614 0.004
DCIV28 06/06/1995 7395.406 0.512 131.6 0.389 7.614 0.051
DCIV29 07/06/1995 2094.106 0.125 160.6 0.078 7.614 0.010
DCIV30 07/06/1995 7001.029 2.693 160.6 1.677 7.614 0.220
DCIV31 07/06/1995 1253.147 0.075 160.6 0.047 7.614 0.006
DCIV32 08/06/1995 16144.330 0.967 152.1 0.636 7.614 0.083
DCIV33 08/06/1995 -413.147 -0.025 152.1 -0.016 7.614 -0.002
DCIV34 08/06/1995 -4171.298 -0.250 152.1 -0.164 7.614 -0.022
DCIV35 08/06/1995 -9315.686 -0.558 152.1 -0.367 7.614 -0.048
DCIV36 15/04/1994 2625.271 0.370 160.0 0.231 7.614 0.030
DCIV37 15/04/1994 13485.317 33.713 160.0 21.071 7.614 2.767
DCIV38 29/04/1994 2108.899 1.004 148.1 0.678 7.614 0.089
DCIV39 29/04/1994 7232.441 0.991 148.1 0.669 7.614 0.088
DCIV40 18/04/1994 15057.543 2.121 190.0 1.116 7.614 0.147
DCIV41 18/04/1994 8841.629 5.052 190.0 2.659 7.614 0.349
DCIV42 05/06/1995 271.461 0.019 121.3 0.015 7.614 0.002
DCIV43 05/06/1995 -6355.689 -0.440 121.3 -0.363 7.614 -0.048
DCIV44 05/06/1995 2372.379 0.164 121.3 0.135 7.614 0.018
DCIV45 05/06/1995 26572.021 1.839 121.3 1.516 7.614 0.199
DCIV46 08/06/1995 6701.613 0.401 152.1 0.264 7.614 0.035
DCIV47 07/06/1995 1067.573 0.411 160.6 0.256 7.614 0.034
DCIV48 17/12/1997 -2090.567 -0.143 147.1 -0.304 7.614 -0.040
DCIV49 17/12/1997 4208.251 0.288 147.1 0.612 7.614 0.080
DCIV55 17/12/1997 -1046.281 -0.072 147.1 -0.152 7.614 -0.020
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a p p e n d ix  iv. Counts for DCIS for DCIS in association with invasive disease - HER2
Patient ID Batch Date Formula Formula/hr/100 Conversion Factor Receptors Normal ReceptorsXN
DCIV60 04/02/97 6320.071 1.317 19.66 25.886 8.557 3.025
DCIV14 25/01/95 14058.865 35.147 44.62 1568.266 8.557 183.271
DCIV27 16/01/97 6849.720 0.590 11.33 6.690 8.557 0.782
DCIV28 16/01/97 4402.949 0.380 11.33 4.300 8.557 0.503
DCIV26 16/01/97 10434.033 0.899 11.33 10.191 8.557 1.191
DCIV10 23/01/95 4387.053 0.914 37.64 34.402 8.557 4.020
DCIV35 04/02/97 10636.380 26.591 19.66 522.778 8.557 61.093
DCIV17 23/01/95 4705.118 0.490 37.64 18.448 8.557 2.156
DCIV46 04/02/97 12054.224 1.256 19.66 24.686 8.557 2.885
DCIV3 23/01/95 10903.565 2.272 37.64 85.502 8.557 9.992
DCIV29 03/02/97 22669.817 56.675 10.95 620.586 8.557 72.523
DCIV47 03/02/97 39392.694 98.482 10.95 1078.375 8.557 126.021
DCIV1 24/01/95 3789.882 0.790 37.28 29.435 8.557 3.440
DCIV41 28/06/94 9190.809 1.915 8.60 16.467 8.557 1.924
DCIV21 04/02/97 7536.182 3.140 19.66 61.734 8.557 7.214
DCIV30 03/02/97 28422.637 71.057 10.95 778.070 8.557 90.927
DCIV5 25/01/95 20267.126 50.668 44.62 2260.798 8.557 264.201
DCIV63 13/01/97 9790.104 0.844 15.86 13.385 8.557 1.564
DCIV62 03/02/97 21933.723 54.834 10.95 600.436 8.557 70.168
DCIV25 16/01/97 53466.851 22.278 11.33 252.408 8.557 29.497
DCIV18 23/01/95 8767.879 0.913 37.64 34.377 8.557 4.017
DCIV61 24/01/95 6288.592 1.310 37.28 48.841 8.557 5.708
DCIV44 13/01/97 4069.754 1.696 15.86 26.894 8.557 3.143
DCIV34 04/02/97 20047.943 2.088 19.66 41.057 8.557 4.798
DCIV59 04/02/97 8969.050 1.869 19.66 36.736 8.557 4.293
DCIV22 04/02/97 29547.777 3.078 19.66 60.511 8.557 7.071
DCIV31 03/02/97 11604.212 1.209 10.95 13.236 8.557 1.547
DCIV37 04/07/94 70319.596 175.799 15.78 2774.108 8.557 324.187
DCIV40 28/06/94 13228.025 1.102 8.60 9.480 8.557 1.108
DCIV45 13/01/97 7834.803 0.675 15.86 10.712 8.557 1.252
DCIV39 11/07/94 1291.989 3.691 12.49 46.106 8.557 5.388
DCIV24 13/01/97 14685.299 6.119 15.86 97.045 8.557 11.341
DCIV57 16/01/97 1166.642 0.101 11.33 1.139 8.557 0.133
DCIV32 04/02/97 31753.115 13.230 19.66 260.111 8.557 30.397
DCIV58 04/07/94 18364.417 1.583 15.78 24.982 8.557 2.919
DCIV48 04/02/97 5813.934 0.606 19.66 11.906 8.557 1.391
DCIV2 25/01/95 3156.730 0.329 44.62 14.672 8.557 1.715
DCIV23 13/01/97 6659.739 0.574 15.86 9.105 8.557 1.064
DCIV36 04/07/94 7900.864 0.681 15.78 10.748 8.557 1.256
DCIV42 13/01/97 8743.012 21.858 15.86 346.660 8.557 40.511
DCIV43 13/01/97 9103.450 0.785 15.86 12.447 8.557 1.455
DCIV15 23/01/95 5811.677 1.211 37.64 45.573 8.557 5.326
DCIV8 23/01/95 4468.321 0.931 37.64 35.039 8.557 4.095
DCIV20 04/02/97 718.985 0.075 19.66 1.472 8.557 0.172
DCIV55 22/12/97 4748.376 0.325 69.10 22.473 8.557 2.626
DCIV56 22/12/97 3924.062 0.269 69.10 18.572 8.557 2.170
DCIV49 22/12/97 1959.688 0.134 69.10 9.275 8.557 1.084
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APPENDIX V Counts for invasive disease - EGFR
Patient ID EGFRXN Patient ID EGFRXN Patient ID EGFRXN
EGFRINV1 0.050 EGFRINV65 0.054 EGFRINV129 0.043
EGFRINV2 0.029 EGFRINV66 0.035 EGFRINV130 0.018
EGFRINV3 0.033 EGFRINV67 0.038 EGFRINV131 0.066
EGFRINV4 0.079 EGFRINV68 0.709 EGFRINV132 0.027
EGFRINV5 0.119 EGFRINV69 0.028 EGFRINV133 0.000
EGFRINV6 0.130 EGFRINV70 0.016 EGFRINV134 0.058
EGFRINV7 0.117 EGFRINV71 0.233 EGFRINV135 0.059
EGFRINV8 0.000 EGFRINV72 0.046 EGFRINV136 0.158
EGFRINV9 0.067 EGFRINV73 0.020 EGFRINV137 0.048
EGFRINV10 0.004 EGFRINV74 0.649 EGFRINV138 0.159
EGFRINV11 0.038 EGFRINV75 0.146 EGFRINV139 0.215
EGFRINV12 0.003 EGFRINV76 0.021 EGFRINV140 0.000
EGFRINV13 0.000 EGFRINV77 0.068 EGFRINV141 0.071
EGFRINV14 0.071 EGFRINV78 0.000 EGFRINV142 0.072
EGFRINV15 0.041 EGFRINV79 0.015 EGFRINV143 0.040
EGFRINV16 0.053 EGFRINV80 0.034 EGFRINV144 0.053
EGFRINV17 0.000 EGFRINV81 0.018 EGFRINV145 0.063
EGFRINV18 0.016 EGFRINV82 0.027 EGFRINV146 0.045
EGFRINV19 0.346 EGFRINV83 0.028 EGFRINV147 0.683
EGFRINV20 0.636 EGFRINV84 0.086 EGFRINV148 0.098
EGFRINV21 0.322 EGFRINV85 0.000 EGFRINV149 0.243
EGFRINV22 0.047 EGFRINV86 0.071 EGFRINV150 0.007
EGFRINV23 1.754 EGFRINV87 0.110 EGFRINV151 0.340
EGFRINV24 0.239 EGFRINV88 0.180 EGFRINV152 0.802
EGFRINV25 0.474 EGFRINV89 0.722 EGFRINV153 0.009
EGFRINV26 0.010 EGFRINV90 0.021 EGFRINV154 0.022
EGFRINV27 0.007 EGFRINV91 0.032 EGFRINV155 0.036
EGFRINV28 0.078 EGFRINV92 0.369 EGFRINV156 0.000
EGFRINV29 0.045 EGFRINV93 0.455 EGFRINV157 0.011
EGFRINV30 0.000 EGFRINV94 0.000 EGFRINV158 0.017
EGFRINV31 0.003 EGFRINV95 0.042 EGFRINV159 0.023
EGFRINV32 0.025 EGFRINV96 0.048 EGFRINV160 0.000
EGFRINV33 0.288 EGFRINV97 0.113 EGFRINV161 1.784
EGFRINV34 0.404 EGFRINV98 0.324 EGFRINV162 0.061
EGFRINV35 0.410 EGFRINV99 0.031 EGFRINV163 0.069
EGFRINV36 0.017 EGFRINV100 0.070 EGFRINV164 0.079
EGFRINV37 0.024 EGFRINV101 0.011 EGFRINV165 0.479
EGFRINV38 0.043 EGFRINV102 0.036 EGFRINV166 0.610
EGFRINV39 0.031 EGFRINV103 0.654 EGFRINV167 2.437
EGFRINV40 0.758 EGFRINV104 0.043 EGFRINV168 0.069
EGFRINV41 0.201 EGFRINV105 0.015 EGFRINV169 7.074
EGFRINV42 0.030 EGFRINV106 0.020 EGFRINV170 0.038
EGFRINV43 0.032 EGFRINV107 2.314 EGFRINV171 0.076
EGFRINV44 0.459 EGFRINV108 0.018 EGFRINV172 0.189
EGFRINV45 0.271 EGFRINV109 0.309 EGFRINV173 0.008
EGFRINV46 0.000 EGFRINV110 0.065 EGFRINV174 0.052
EGFRINV47 0.093 EGFRINV111 0.013 EGFRINV175 0.057
EGFRINV48 0.578 EGFRINV112 0.053 EGFRINV176 0.038
EGFRINV49 0.194 EGFRINV113 0.506 EGFRINV177 0.056
EGFRINV50 0.269 EGFRINV114 0.000 EGFRINV178 0.000
EGFRINV51 0.239 EGFRINV115 0.050 EGFRINV179 0.128
EGFRINV52 0.043 EGFRINV116 0.259 EGFRINV180 0.023
EGFRINV53 0.026 EGFRINV117 0.025 EGFRINV181 0.022
EGFRINV54 0.079 EGFRINV118 0.027 EGFRINV182 0.294
EGFRINV55 0.157 EGFRINV119 0.000 EGFRINV183 0.040
EGFRINV56 0.168 EGFRINV120 0.053 EGFRINV184 0.004
EGFRINV57 0.189 EGFRINV121 0.009 EGFRINV185 0.013
EGFRINV58 0.047 EGFRINV122 0.035 EGFRINV186 0.074
EGFRINV59 0.319 EGFRINV123 0.012 EGFRINV187 0.145
EGFRINV60 0.711 EGFRINV124 0.023 EGFRINV188 0.016
EGFRINV61 0.033 EGFRINV125 0.239 EGFRINV189 0.023
EGFRINV62 0.097 EGFRINV126 0.044 EGFRINV190 0.008
EGFRINV63 0.034 EGFRINV127 0.050 EGFRINV191 0.028
EGFRINV64 0.030 EGFRINV128 0.047 EGFRINV192 0.000
EGFRINV193 0.470
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a ppe n d ix  vi C ounts for invasive d isease  - HER2
Patient ID B2INVXN Patient ID B2INVXN Patient ID B2INVXN
B2INV1 3.16 B2INV60 10.56 B2INV119 31.43
B2INV2 1.96 B2INV61 4.71 B2INV120 1.4
B2INV3 2.61 B2INV62 0.21 B2INV121 4.89
B2INV4 0.84 B2INV63 2.32 B2INV122 1.24
B2INV5 1.52 B2INV64 2.99 B2INV123 5.54
B2INV6 3.4 B2INV65 3.04 B2INV124 1.49
B2INV7 5.75 B2INV66 159.02 B2INV125 94.1
B2INV8 1.19 B2INV67 0.37 B2INV126 7.08
B2INV9 5.05 B2INV68 2.14 B2INV127 157.47
B2INV10 0.96 B2INV69 8.8 B2INV128 3.7
B2INV11 0.31 B2INV70 3.24 B2INV129 1.3
B2INV12 6.2 B2INV71 0.95 B2INV130 2.33
B2INV13 21.44 B2INV72 1.12 B2INV131 0.84
B2INV14 28.05 B2INV73 144.94 B2INV132 1.6
B2INV15 2.7 B2INV74 0.59 B2INV133 5.79
B2INV16 4.59 B2INV75 3.52 B2INV134 5.67
B2INV17 5.89 B2INV76 6.52 B2INV135 0.92
B2INV18 79.41 B2INV77 112.89 B2INV136 3.71
B2INV19 1.05 B2INV78 1.55 B2INV137 2.76
B2INV20 3.81 B2INV79 0.73 B2INV138 4.5
B2INV21 136.37 B2INV80 30.93 B2INV139 154.58
B2INV22 0.83 B2INV81 173.75 B2INV140 5.1
B2INV23 2.05 B2INV82 0.72 B2INV141 1.21
B2INV24 3.56 B2INV83 5.37 B2INV142 0.92
B2INV25 63.21 B2INV84 17.08 B2INV143 3.57
B2INV26 125.79 B2INV85 1.05 B2INV144 2.01
B2INV27 3.46 B2INV86 1.56 B2INV145 2.59
B2INV28 2.01 B2INV87 6.82 B2INV146 2.5
B2INV29 286.67 B2INV88 5.12 B2INV147 4.67
B2INV30 2.67 B2INV89 29.34 B2INV148 6.2
B2INV31 2.34 B2INV90 90.06 B2INV149 36.67
B2INV32 8.24 B2INV91 0.33 B2INV150 0.04
B2INV33 35.24 B2INV92 293.57 B2INV151 1.31
B2INV34 4.37 B2INV93 1.7 B2INV152 1.7
B2INV35 2.23 B2INV94 44.81 B2INV153 3.61
B2INV36 1.63 B2INV95 324.34 B2INV154 2.43
B2INV37 7.67 B2INV96 1.49 B2INV155 192.16
B2INV38 0.14 B2INV97 3.44 B2INV156 1.36
B2INV39 2 B2INV98 10.03 B2INV157 6
B2INV40 1.63 B2INV99 1.35 B2INV158 0.76
B2INV41 43.47 B2INV100 133.31 B2INV159 2.77
B2INV42 2.55 B2INV101 159.97 B2INV160 3.26
B2INV43 3.8 B2INV102 0.94 B2INV161 1.14
B2INV44 213.98 B2INV103 3 B2INV162 2.98
B2INV45 0.14 B2INV104 3.08 B2INV163 3.9
B2INV46 0.44 B2INV105 4.06 B2INV164 214.13
B2INV47 1.88 B2INV106 0.61 B2INV165 18.29
B2INV48 3.76 B2INV107 1.87 B2INV166 1.39
B2INV49 36.94 B2INV108 35.18 B2INV167 10.73
B2INV50 19.22 B2INV109 1.98 B2INV168 5.59
B2INV51 198.07 B2INV110 3.35 B2INV169 1.72
B2INV52 0.64 B2INV111 5.89 B2INV170 90.47
B2INV53 1.22 B2INV112 478.58 B2INV171 1.59
B2INV64 9.08 B2INV113 15.29 B2INV172 0.85
B2INV55 22.8 B2INV114 1.95 B2INV173 6.33
B2INV56 2.94 B2INV115 369.05 B2INV174 6.58
B2INV57 31.99 B2INV116 1.47 B2INV175 1.39
B2INV58 0.74 B2INV117 2.16 B2INV176 2.08
B2INV59 2.63 B2INV118 3.05 B2INV177 5.79
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